

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111-3834
(415) 576-0200

BOX SEQUENCE
ASST. COMMISSIONER FOR PATENTS
Washington, D. C. 20231

Sir:

Transmitted herewith for filing is the
[] patent application of
[] design patent application of
[x] continuation-in-part patent application of

Inventor(s): *1-00 et al* Joe W. Gray, Colin Collins, Soo-in Hwang, Tony Godfrey, David Kowbel and Johanna Rommens

For: GENES FROM THE 20q13 AMPLICON AND THEIR USES

[x] This application claims priority from each of the following Application Nos./filing dates:
08/680,395 /7/15/96 ; 08/731,499 /10/16/96 ; _____ / _____.

[] Please amend this application by adding the following before the first sentence: --This application claims the benefit of U.S. Provisional Application No. 60/_____, filed _____, the disclosure of which is incorporated by reference.--

Enclosed are:

[x] 6 sheet(s) of [] formal [x] informal drawing(s).
[] An assignment of the invention to _____
[] A [] signed [] unsigned Declaration & Power of Attorney.
[X] A [] signed [X] unsigned Declaration.
[] A Power of Attorney.
[] A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27 [] is enclosed [] was filed in the earliest of the above-identified patent application(s).
[] A certified copy of a _____ application.
[] Information Disclosure Statement under 37 CFR 1.97.
[] A petition to extend time to respond in the parent application of this continuation-in-part application.
[]

In view of the Unsigned Declaration as filed with this application and pursuant to 37 CFR §1.53(d),
Applicant requests deferral of the filing fee until submission of the Missing Parts of Application.

DO NOT CHARGE THE FILING FEE AT THIS TIME.

Telephone:
(415) 576-0200
APPNOFEE.TRN y
y11/96

Eugenia Garrett-Wackowski
Reg. No.: 37,330
Attorneys for Applicant

08/785532 A/m

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111-3834
(415) 576-0200



Atty. Docket No. 023070-068911

"Express Mail" Label No. EM530419608US

Date of Deposit January 17, 1997

BOX SEQUENCE
ASST. COMMISSIONER FOR PATENTS
Washington, D. C. 20231

Sir:

Transmitted herewith for filing is the
[] patent application of
[] design patent application of
[x] continuation-in-part patent application of

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Asst. Commissioner for Patents, Washington, D. C. 20231

By Sharon Piatt
Sharon Piatt

Inventor(s): Joe W. Gray, Colin Collins, Soo-in Hwang, Tony Godfrey, David Kowbel and Johanna Rommens

For: GENES FROM THE 20q13 AMPLICON AND THEIR USES

[x] This application claims priority from each of the following Application Nos./filing dates:
08/680,395 /7/15/96 ; 08/731,499 /10/16/96 ; _____ / _____ .

[] Please amend this application by adding the following before the first sentence: --This application claims the benefit of U.S. Provisional Application No. 60/_____, filed _____, the disclosure of which is incorporated by reference.--

Enclosed are:

[x] 6 sheet(s) of [] formal [x] informal drawing(s).
[] An assignment of the invention to _____.
[] A [] signed [] unsigned Declaration & Power of Attorney.
[X] A [] signed [X] unsigned Declaration.
[] A Power of Attorney.
[] A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27 [] is enclosed [] was filed in the earliest of the above-identified patent application(s).
[] A certified copy of a _____ application.
[] Information Disclosure Statement under 37 CFR 1.97.
[] A petition to extend time to respond in the parent application of this continuation-in-part application.
[]

In view of the Unsigned Declaration as filed with this application and pursuant to 37 CFR §1.53(d),
Applicant requests deferral of the filing fee until submission of the Missing Parts of Application.

DO NOT CHARGE THE FILING FEE AT THIS TIME.

Telephone:
(415) 576-0200
APPNO/FEETRNY
y11/96

Eugenia Garrett-Wackowski
Reg. No.: 37,330

Attorneys for Applicant



Attorney Docket No. 02307O-0689-1-1

PATENT APPLICATION

GENES FROM THE 20q13 AMPLICON AND THEIR USES

Inventors:

Joe W. Gray
Colin Collins
Soo-in Hwang
Tony Godfrey
David Kowbel
Johanna Rommens

Assignee:

Regents of the University of California

Entity:

TOWNSEND and TOWNSEND and CREW
Two Embarcadero Center, 8th Floor
San Francisco, CA, 94111-3834



GENES FROM 20q13 AMPLICON AND THEIR USES

5

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of USSN 08/731,499 filed on October 16, 1996 and USSN 08/680,395 filed on July 15, 1996, which is related to copending U.S. Patent Application, USSN 08/546,130, filed October 20, 1995, each of which is incorporated herein by reference for all purposes.

10

BACKGROUND OF THE INVENTION

This invention pertains to the field of cytogenetics. More particularly this invention pertains to the identification of genes in a region of amplification at about 20q13 in various cancers. The genes disclosed here can be used as probes specific for the 20q13 amplicon as well as for treatment of various cancers.

15

Chromosome abnormalities are often associated with genetic disorders, degenerative diseases, and cancer. In particular, the deletion or multiplication of copies of whole chromosomes or chromosomal segments, and higher level amplifications of specific regions of the genome are common occurrences in cancer. See, for example Smith, *et al.*, *Breast Cancer Res. Treat.*, 18: Suppl. 1: 5-14 (1991), van de Vijer & Nusse, *Biochim. Biophys. Acta* 1072: 33-50 (1991), Sato, *et al.*, *Cancer. Res.*, 50: 7184-7189 (1990). In fact, the amplification and deletion of DNA sequences containing proto-oncogenes and tumor-suppressor genes, respectively, are frequently characteristic of tumorigenesis. Dutrillaux, *et al.*, *Cancer Genet. Cytogenet.*, 49: 203-217 (1990). Clearly, the identification of amplified and deleted regions and the cloning of the genes involved is crucial both to the study of tumorigenesis and to the development of cancer diagnostics.

20

25

30

The detection of amplified or deleted chromosomal regions has traditionally been done by cytogenetics. Because of the complex packing of DNA into the chromosomes, resolution of cytogenetic techniques has been limited to regions larger than about 10 Mb; approximately the width of a band in Giemsa-stained chromosomes. In complex karyotypes with multiple translocations and other genetic changes, traditional cytogenetic analysis is of little utility because karyotype information is lacking or cannot be interpreted. Teyssier, J.R., *Cancer Genet. Cytogenet.*, 37: 103 (1989). Furthermore,

conventional cytogenetic banding analysis is time consuming, labor intensive, and frequently difficult or impossible.

More recently, cloned probes have been used to assess the amount of a given DNA sequence in a chromosome by Southern blotting. This method is effective even if the genome is heavily rearranged so as to eliminate useful karyotype information. However, Southern blotting only gives a rough estimate of the copy number of a DNA sequence, and does not give any information about the localization of that sequence within the chromosome.

Comparative genomic hybridization (CGH) is a more recent approach to identify the presence and localization of amplified/deleted sequences. See Kallioniemi, *et al.*, *Science*, 258: 818 (1992). CGH, like Southern blotting, reveals amplifications and deletions irrespective of genome rearrangement. Additionally, CGH provides a more quantitative estimate of copy number than Souther blotting, and moreover also provides information of the localization of the amplified or deleted sequence in the normal chromosome.

Using CGH, the chromosomal 20q13 region has been identified as a region that is frequently amplified in cancers (*see, e.g.* U.S. Patent No.). Initial analysis of this region in breast cancer cell lines identified a region approximately 2 Mb on chromosome 20 that is consistently amplified.

SUMMARY OF THE INVENTION

The present invention relates to the identification of a narrow region (about 600 kb) within a 2 Mb amplicon located at about chromosome 20q13 (more precisely at 20q13.2) that is consistently amplified in primary tumors. In addition, this invention provides cDNA sequences from a number of genes which map to this region. These sequences are useful as probes or as probe targets for monitoring the relative copy number of corresponding sequences from a biological sample such as a tumor cell. Also provided is a contig (a series of clones that contiguously spans this amplicon) which can be used to prepare probes specific for the amplicon. The probes can be used to detect chromosomal abnormalities at 20q13.

Thus, in one embodiment, this invention provides a method of detecting a chromosome abnormality (*e.g.*, an amplification or a deletion) at about position FLpter 0.825 on human chromosome 20 (20q13.2). The method involves contacting a chromosome sample from a patient with a composition consisting essentially of one or

more labeled nucleic acid probes each of which binds selectively to a target polynucleotide sequence at about position FLpter 0.825 on human chromosome 20 under conditions in which the probe forms a stable hybridization complex with the target sequence; and detecting the hybridization complex. The step of detecting the 5 hybridization complex can involve determining the copy number of the target sequence. The probe preferably comprises a nucleic acid that specifically hybridizes under stringent conditions to a nucleic acid selected from the nucleic acids disclosed here. Even more preferably, the probe comprises a subsequence selected from sequences set forth in SEQ. ID. Nos. 1-10 and 12. The probe is preferably labeled, and is more preferably labeled 10 with digoxigenin or biotin. In one embodiment, the hybridization complex is detected in interphase nuclei in the sample. Detection is preferably carried out by detecting a fluorescent label (*e.g.*, FITC, fluorescein, or Texas Red). The method can further involve contacting the sample with a reference probe which binds selectively to a chromosome 20 centromere.

15 This invention also provides for two new genes, ZABC1 and 1b1, in the 20q13.2 region that are both amplified and overexpressed in a variety of cancers. ZABC1 is a putative zinc finger protein. Zinc finger proteins are found in a variety of transcription factors, and amplification or overexpression of transcription factors typically results in cellular mis-regulation. ZABC1 and 1b1 thus appear to play an important role 20 in the etiology of a number of cancers.

This invention provides for a new human cyclophilin nucleic acid (SEQ ID NO 13). Cyclophilin nucleic acids have been implicated in a variety of cellular processes, including signal transduction.

25 This invention also provides for proteins encoded by nucleic acid sequences in the 20q13 amplicon (SEQ. ID. Nos: 1-10 and 12-13) and subsequences, more preferably subsequences of at least 10 amino acids, preferably of at least 20 amino acids and most preferably of at least 30 amino acids in length. Particularly preferred subsequences are epitopes specific to the 20q13 proteins, more preferably epitopes specific to the ZABC1 and 1b1 proteins. Such proteins include, but are not limited to 30 isolated polypeptides comprising at least 20 amino acids from a polypeptide encoded by the nucleic acids of SEQ. ID No. 1-10 and 12-13 or from the polypeptide of SEQ. ID. No. 11 wherein the polypeptide, when presented as an immunogen, elicits the production of an antibody which specifically binds to a polypeptide selected from the group

consisting of a polypeptide encoded by the nucleic acids of SEQ. ID No. 1-10 and 12-13 or from the polypeptide of SEQ. ID. No. 11, where the polypeptide does not bind to antisera raised against a polypeptide selected from the group consisting of a polypeptide encoded by the nucleic acids of SEQ. ID No. 1-10 and 12-13 or from the polypeptide of SEQ. ID. No. 11 which has been fully immunosorbed with a polypeptide selected from the group consisting of a polypeptide encoded by the nucleic acids of SEQ. ID No. 1-10 and 12-13 or from the polypeptide of SEQ. ID. No. 11. In preferred embodiments, the polypeptides of the invention hybridize to antisera raised against a polypeptide encoded by those encoded by SEQ ID NOS. 1-13, where the antisera has been immusorbed with the most structurally related previously known polypeptide. For example, a polypeptide of the invention binds to antisera raised against a polypeptide encoded by SEQ ID NO. 13, wherein the antisera has been immusorbed with a rat or mouse cyclophilin polypeptide (Rat cyclophilin nucleic acids are known; *see*, GenBank™ under accession No. M19533; Mouse cyclophilin nucleic acids are known; *see*, GenBank™ under accession No. 50620. cDNAs from the mouse and rat cyclophilin cDNAs are about 85% identical to SEQ ID NO. 13).

In another embodiment, the method can involve detecting a polypeptide (protein) encoded by a nucleic acid (ORF) in the 20q13 amplicon. The method may include any of a number of well known protein detection methods including, but not limited to, the protein assays disclosed herein.

This invention also provides cDNA sequences from genes in the amplicon (SEQ. ID. Nos. 1-10 and 12-13). The nucleic acid sequences can be used in therapeutic applications according to known methods for modulating the expression of the endogenous gene or the activity of the gene product. Examples of therapeutic approaches include antisense inhibition of gene expression, gene therapy, monoclonal antibodies that specifically bind the gene products, and the like. The genes can also be used for recombinant expression of the gene products *in vitro*.

This invention also provides for proteins (*e.g.*, SEQ. ID. No. 11) encoded by the cDNA sequences from genes in the amplicon (*e.g.*, SEQ. ID. Nos. 1-10 and 12-13). Where the amplified nucleic acids include cDNA which are expressed, detection and/or quantification of the protein expression product can be used to identify the presence or absence or quantify the amplification level of the amplicon or of abnormal protein products produced by the amplicon.

The probes disclosed here can be used in kits for the detection of a chromosomal abnormality at about position FLpter 0.825 on human chromosome 20. The kits include a compartment which contains a labeled nucleic acid probe which binds selectively to a target polynucleotide sequence at about FLpter 0.825 on human
5 chromosome 20. The probe preferably includes at least one nucleic acid that specifically hybridizes under stringent conditions to a nucleic acid selected from the nucleic acids disclosed here. Even more preferably, the probes comprise one or more nucleic acids selected from the nucleic acids disclosed here. In a preferred embodiment, the probes are labelled with digoxigenin or biotin. The kit may further include a reference probe
10 specific to a sequence in the centromere of chromosome 20.

Definitions

A "chromosome sample" as used herein refers to a tissue or cell sample prepared for standard *in situ* hybridization methods described below. The sample is prepared such that individual chromosomes remain substantially intact and typically
15 comprises metaphase spreads or interphase nuclei prepared according to standard techniques.

"Nucleic acid" refers to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, would encompass known analogs of natural nucleotides that can function in a similar manner as naturally
20 occurring nucleotides.

An "isolated" polynucleotide is a polynucleotide which is substantially separated from other contaminants that naturally accompany it, e.g., protein, lipids, and other polynucleotide sequences. The term embraces polynucleotide sequences which have been removed or purified from their naturally-occurring environment or clone
25 library, and include recombinant or cloned DNA isolates and chemically synthesized analogues or analogues biologically synthesized by heterologous systems.

"Subsequence" refers to a sequence of nucleic acids that comprise a part of a longer sequence of nucleic acids.

A "probe" or a "nucleic acid probe", as used herein, is defined to be a collection of one or more nucleic acid fragments whose hybridization to a target can be detected. The probe is labeled as described below so that its binding to the target can be detected. The probe is produced from a source of nucleic acids from one or more particular (preselected) portions of the genome, for example one or more clones, an
30

isolated whole chromosome or chromosome fragment, or a collection of polymerase chain reaction (PCR) amplification products. The probes of the present invention are produced from nucleic acids found in the 20q13 amplicon as described herein. The probe may be processed in some manner, for example, by blocking or removal of repetitive nucleic acids or enrichment with unique nucleic acids. Thus the word "probe" may be used herein to refer not only to the detectable nucleic acids, but to the detectable nucleic acids in the form in which they are applied to the target, for example, with the blocking nucleic acids, *etc.* The blocking nucleic acid may also be referred to separately. What "probe" refers to specifically is clear from the context in which the word is used.

"Hybridizing" refers the binding of two single stranded nucleic acids via complementary base pairing.

"Bind(s) substantially" or "binds specifically" or "binds selectively" or "hybridizes specifically" refer to complementary hybridization between an oligonucleotide and a target sequence and embraces minor mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired detection of the target polynucleotide sequence. These terms also refer to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture (*e.g.*, total cellular) DNA or RNA. The term "stringent conditions" refers to conditions under which a probe will hybridize to its target subsequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. "Stringent hybridization" and "Stringent hybridization wash conditions" in the context of nucleic acid hybridization experiments such as CGH, FISH, Southern and northern hybridizations are sequence dependent, and are different under different environmental parameters. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) *Laboratory Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes* part I chapter 2 "overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York. Generally, highly stringent hybridization and wash conditions are selected to be about 5° C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at

which 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to be equal to the T_m for a particular probe.

An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or northern blot is 50% formalin with 1 mg of heparin at 42°C, with the hybridization being carried out overnight. An example of stringent wash conditions is a .2x SSC wash at 65°C for 15 minutes (*see, Sambrook, supra* for a description of SSC buffer). Often, the high stringency wash is preceded by a low stringency wash to remove background probe signal. An example medium stringency wash for a duplex of, e.g., about 100 nucleotides or more, is 1x SSC at 45°C for 15 minutes. An example low stringency wash for a duplex of, e.g., more than 100 nucleotides, is 4x SSC at 40°C for 15 minutes. In general, a signal to noise ratio of 2x (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

One of skill will recognize that the precise sequence of the particular probes described herein can be modified to a certain degree to produce probes that are "substantially identical" to the disclosed probes, but retain the ability to bind substantially to the target sequences. Such modifications are specifically covered by reference to the individual probes herein. The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 90% sequence identity, more preferably at least 95%, compared to a reference sequence using the methods described below using standard parameters.

Two nucleic acid sequences are said to be "identical" if the sequence of nucleotides in the two sequences is the same when aligned for maximum correspondence as described below. The term "complementary to" is used herein to mean that the complementary sequence is identical to all or a portion of a reference polynucleotide sequence. Nucleic acids which do not hybridize to complementary versions of each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

Sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two sequences over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window", as

used herein, refers to a segment of at least about 20 contiguous positions, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

5 Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman *Adv. Appl. Math.* 2: 482 (1981), by the homology alignment algorithm of Needleman and Wunsch *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson and Lipman *Proc. Natl. Acad. Sci. (U.S.A.)* 85: 2444 (1988), by computerized implementations of these algorithms.

10 "Percentage of sequence identity" is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to the same nucleic acid sequence under stringent conditions.

15 "Conservatively modified variations" of a particular nucleic acid sequence refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given polypeptide. For instance, the codons CGU, CGC, CGA, CGG, AGA, and AGG all encode the amino acid arginine. Thus, at every position where an arginine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of "conservatively modified variations." Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine) can be modified to yield a functionally identical molecule by

standard techniques. Accordingly, each "silent variation" of a nucleic acid which encodes a polypeptide is implicit in each described sequence. Furthermore, one of skill will recognize that individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (typically less than 5%, more typically less than 1%) in an encoded sequence are "conservatively modified variations" where the alterations result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another:

- 10 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 15 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

The term "20q13 amplicon protein" is used herein to refer to proteins encoded ORFs in the 20q13 amplicon disclosed herein. Assays that detect 20q13 amplicon proteins are intended to detect the level of endogenous (native) 20q13 amplicon proteins present in subject biological sample. However, exogenous 20q13 amplicon proteins (from a source extrinsic to the biological sample) may be added to various assays to provide a label or to compete with the native 20q13 amplicon protein in binding to an anti-20q13 amplicon protein antibody.. One of skill will appreciate that a 20q13 amplicon protein mimetic may be used in place of exogenous 20q13 protein in this context. A "20q13 protein", as used herein, refers to a molecule that bears one or more 20q13 amplicon protein epitopes such that it is specifically bound by an antibody that specifically binds a native 20q13 amplicon protein.

As used herein, an "antibody" refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon,

which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

The basic immunoglobulin (antibody) structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (V_L) and variable heavy chain (V_H) refer to these light and heavy chains respectively.

Antibodies may exist as intact immunoglobulins or as a number of well characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce $F(ab)'_2$, a dimer of Fab which itself is a light chain joined to V_H-C_H1 by a disulfide bond. The $F(ab)'_2$ may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the $F(ab)'_2$ dimer into an Fab' monomer. The Fab' monomer is essentially an Fab with part of the hinge region (see, *Fundamental Immunology*, W.E. Paul, ed., Raven Press, N.Y. (1993) for a more detailed description of other antibody fragments). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such Fab' fragments may be synthesized *de novo* either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein also includes antibody fragments either produced by the modification of whole antibodies or synthesized *de novo* using recombinant DNA methodologies.

The phrase "specifically binds to a protein" or "specifically immunoreactive with", when referring to an antibody refers to a binding reaction which is determinative of the presence of the protein in the presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to a protein under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, antibodies can be raised to the a 20q13 amplicon protein that bind the 20q13 amplicon protein and not to any other proteins present in a biological sample. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA

immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1(A) shows disease-free survival of 129 breast cancer patients according to the level of 20q13 amplification. Patients with tumors having high level 20q13 amplification have a shorter disease-free survival ($p=0.04$ by Mantel-Cox test) compared to those having no or low level amplification.

10

Figure 1(B) Shows the same disease-free survival difference of Figure 4(A) in the sub-group of 79 axillary node-negative patients ($p=0.0022$ by Mantel-Cox test).

15

Figure 2 shows a comparison of 20q13 amplification detected by FISH in a primary breast carcinoma and its metastasis from a 29-year patient. A low level amplification of 20q13 (20q13 compared to 20p reference probe) was found in the primary tumor. The metastasis, which appeared 8 months after mastectomy, shows a high level amplification of the chromosome 20q13 region. The overall copy number of chromosome 20 (20p reference probe) remained unchanged. Each data point represents gene copy numbers in individual tumor cells analyzed.

20

Figure 3 shows a graphical representation of the molecular cytogenetic mapping and subsequent cloning of the 20q13.2 amplicon. Genetic distance is indicated in centiMorgans (cM). The thick black bar represents the region of highest level amplification in the breast cancer cell line BT474 and covers a region of about 1.5 Mb. P1 and BAC clones are represented as short horizontal lines and YAC clones as heavier horizontal lines. Not all YAC and P1 clones are shown. YACs 957f3, 782c9, 931h12, and 902 are truncated. Sequence tagged sites (STSs) appear as thin vertical lines and open circles indicate that a given YAC has been tested for and is positive for a given STS. Not all STSs have been tested on all YACs. The interval from which more than 100 exons have been trapped is represented as a filled box. The 600 kb interval spanning the region of highest amplification level in primary tumors is represented by the filled black box (labeled Sequence). The lower part of the figure shows the levels of amplification in two primary tumors that further narrow the region of highest amplification to within about 600 kb.

Figure 4 provides a higher resolution map of the amplicon core as defined in primary tumors.

Figure 5 shows the map location of 15 genes in the amplicon.

Figure 6 shows a sequence alignment between Rat cyclophilin and SEQ

5 ID 13.

DETAILED DESCRIPTION

This invention provides a number of cDNA sequences which can be used as probes for the detection of chromosomal abnormalities at 20q13. Studies using comparative genomic hybridization (CGH) have shown that a region at chromosome 10 20q13 is increased in copy number frequently in cancers of the breast (~ 30%), ovary (~ 15%), bladder (~ 30%), head and neck (~ 75%) and colon (~ 80%). This suggests the presence of one or more genes that contribute to the progression of several solid tumors are located at 20q13.

Gene amplification is one mechanism by which dominantly acting oncogenes are overexpressed, allowing tumors to acquire novel growth characteristics and/or resistance to chemotherapeutic agents. Loci implicated in human breast cancer progression and amplified in 10-25% of primary breast carcinomas include the erbB-2 locus (Lupu *et al.*, *Breast Cancer Res. Treat.*, 27: 83 (1993), Slamon *et al.* *Science*, 235: 177-182 (1987), Heiskanen *et al.* *Biotechniques*, 17: 928 (1994)) at 17q12, cyclin-D (Mahadevan *et al.*, *Science*, 255: 1253-1255 (1993), Gillett *et al.*, *Canc. Res.*, 54: 1812 (1994)) at 11q13 and MYC (Gaffey *et al.*, *Mod. Pathol.*, 6: 654 (1993)) at 8q34.

Pangenomic surveys using comparative genomic hybridization (CGH) recently identified about 20 novel regions of increased copy number in breast cancer (Kallioniemi *et al.*, *Genomics*, 20: 125-128 (1994)). One of these loci, band 20q13, was amplified in 18% of primary tumors and 40% of cell lines (Kallioniemi *et al.*, *Genomics*, 20: 125-128 (1994)). More recently, this same region was found amplified in 15% of ovarian, 80% of bladder and 80% of colorectal tumors. The resolution of CGH is limited to 5-10 Mb. Thus, FISH was performed using locus specific probes to confirm the CGH data and precisely map the region of amplification.

30 The 20q13 region has been analyzed in breast cancer at the molecular level and a region, approximately 600 kb wide, that is consistently amplified was identified, as described herein. Moreover, as shown herein, the importance of this amplification in breast cancer is indicated by the strong association between amplification and decreased

patient survival and increased tumor proliferation (specifically, increased fraction of cells in S-phase).

In particular, as explained in detail in Example 1, high-level 20q13 amplification was associated ($p=0.0022$) with poor disease free survival in node-negative patients, compared to cases with no or low-level amplification (Figure 1). Survival of patients with moderately amplified tumors did not differ significantly from those without amplification. Without being bound to a particular theory, it is suggested that an explanation for this observation may be that low level amplification precedes high level amplification. In this regard, it may be significant that one patient developed a local metastasis with high-level 20q13.2 amplification 8 month after resection of a primary tumor with low level amplification (Figure 3).

The 20q13 amplification was associated with high histologic grade of the tumors. This correlation was seen in both moderately and highly amplified tumors. There was also a correlation ($p=0.0085$) between high level amplification of a region complementary to a particular probe, RMC20C001 (Tanner *et al.*, *Cancer Res.*, 54: 4257-4260 (1994)), and cell proliferation, measured by the fraction of cells in S-phase (Figure 4). This finding is important because it identifies a phenotype that can be scored in functional assays, without knowing the mechanism underlying the increased S-phase fraction. The 20q13 amplification did not correlate with the age of the patient, primary tumor size, axillary nodal or steroid hormone-receptor status.

This work localized the 20q13.2 amplicon to an interval of approximately 2 Mb. Furthermore, it suggests that high-level amplification, found in 7% of the tumors, confers an aggressive phenotype on the tumor, adversely affecting clinical outcome. Low level amplification (22% of primary tumors) was associated with pathological features typical of aggressive tumors (high histologic grade, aneuploidy and cell proliferation) but not patient prognosis.

In addition, it is shown herein that the 20q13 amplicon (more precisely the 20q13.2 amplicon) is one of three separate co-amplified loci on human chromosome 20 that are packaged together throughout the genomes of some primary tumors and breast cancer cell lines. No known oncogenes map in the 20q13.2 amplicon.

Identification of 20q13 Amplicon Probes.

Initially, a paucity of available molecular cytogenetic probes dictated that FISH probes be generated by the random selection of cosmids from a chromosome 20

specific library, LA20NC01, and map them to chromosome 20 by digital imaging microscopy. Approximately 46 cosmids, spanning the 70 Mb chromosome, were isolated for which fractional length measurements (FLpter) and band assignments were obtained. Twenty six of the cosmids were used to assay copy number in the breast cancer cell line BT474 by interphase FISH analysis. Copy number was determined by counting hybridization signals in interphase nuclei. This analysis revealed that cosmid RMC20C001 (Flpter, 0.824; 20q13.2), described by Stokke *et al.*, *Genomics*, 26: 134-137 (1995), defined the highest-level amplification (~60 copies/cell) in BT474 cells (Tanner *et al.*, *Cancer Res.*, 54: 4257-4260 (1994)).

P1 clones containing genetically mapped sequences were selected from 20q13.2 and used as FISH probes to confirm and further define the region of amplification. Other P1 clones were selected for candidate oncogenes broadly localized to the 20q13.2 region (Flpter, 0.81-0.84). These were selected from the DuPont P1 library (Shepherd, *et al.*, *Proc. Natl. Acad. Sci. USA*, 92: 2629 (1994), available commercially from Genome Systems), by PCR (Saiki *et al.*, *Science*, 230: 1350 (1985)) using primer pairs developed in the 3' untranslated region of each candidate gene. Gene specific P1 clones were obtained for, protein tyrosine phosphatase (PTPN1, Flpter 0.78), melanocortin 3 receptor (MC3R, Flpter 0.81), phosphoenolpyruvate carboxy kinase (PCK1, Flpter 0.85), zinc finger protein 8 (ZNF8, Flpter 0.93), guanine nucleotide-binding protein (GNAS 1, Flpter .873), src-oncogene (SRC, Flpter 0.669), topoisomerase 1 (TOP1, Flpter 0.675), the bcl-2 related gene bcl-x (Flpter 0.526) and the transcription factor E2F-1 (FLpter 0.541). Each clone was mapped by digital imaging microscopy and assigned Flpter values. Five of these genes (SRC, TOPO1, GNAS1, E2F-1 and BC1-x) were excluded as candidate oncogenes in the amplicon because they mapped well outside the critical region at Flpter 0.81-0.84. Three genes (PTPNR1, PCK-1 and MC3R) localized close enough to the critical region to warrant further investigation.

Interphase FISH on 14 breast cancer cell lines and 36 primary tumors using 24 cosmid and 3 gene specific P1 (PTPNRL, PCK-1 and MC3R) probes found high level amplification in 35% (5/14) of breast cancer cell lines and 8% (3/36) of primary tumors with one or more probe. The region with the highest copy number in 4/5 of the cell lines and 3/3 primary tumors was defined by the cosmid RMC20C001. This indicated that PTPNR1, PCK1 and MC3R could also be excluded as candidates for

oncogenes in the amplicon and, moreover, narrowed the critical region from 10 Mb to 1.5-2.0 Mb (see, Tanner *et al.*, *Cancer Res.*, 54: 4257-4260 (1994)).

Because probe RMC20C001 detected high-level (3 to 10-fold) 20q13.2 amplification in 35% of cell lines and 8% of primary tumors it was used to (1) define the prevalence of amplification in an expanded tumor population, (2) assess the frequency and level of amplification in these tumors, (3) evaluate the association of the 20q13.2 amplicon with pathological and biological features, (4) determine if a relationship exists between 20q13 amplification and clinical outcome and (5) assess 20q13 amplification in metastatic breast tumors.

As detailed in Example 1, fluorescent *in situ* hybridization (FISH) with RMC20C001 was used to assess 20q13.2 amplification in 132 primary and 11 recurrent breast tumors. The absolute copy number (mean number of hybridization signals per cell) and the level of amplification (mean number of signals relative to the p-arm reference probe) were determined. Two types of amplification were found: Low level amplification (1.5-3 fold with FISH signals dispersed throughout the tumor nuclei) and high level amplification (>3 fold with tightly clustered FISH signals). Low level 20q13.2 amplification was found in 29 of the 132 primary tumors (22%), whereas nine cases (6.8%) showed high level amplification.

RMC20C001 and four flanking P1 probes (MC3R, PCK, RMC20C026, and RMC20C030) were used to study the extent of DNA amplification in highly amplified tumors. Only RMC20C001 was consistently amplified in all tumors. This finding confirmed that the region of common amplification is within a 2 Mb interval flanked by but not including PCK-1 and MC3R.

A physical map was assembled to further localize the minimum common region of amplification and to isolate the postulated oncogene(s). The DuPont P1 library (Shepherd *et al.* *Proc. Natl. Acad. Sci. USA*, 91: 2629 (1994) was screened for STSs likely to map in band 20q13.2. P1 clones at the loci D20S102, D20S100, D20S120, D20S183, D20S480, D20S211 were isolated, and FISH localized each to 20q13.2. Interphase FISH analysis was then performed in the breast cancer cell line BT474 to assess the amplification level at each locus. The loci D20S100-D20S120-D20S183-D20S480-D20S211 were highly amplified in the BT474 cell line, whereas D20S102 detected only low level amplification. Therefore, 5 STSs,

spanning 5 cM, were localized within the 20q13.2 amplicon and were utilized to screen the CEPH megaYAC library.

CEPH megaYAC library screening and computer searches of public databases revealed D20S120-D20S183-D20S480-D20S211 to be linked on each of three megaYAC clones y820f5, 773h10, and 931h6 (Figure 3). Moreover, screening the CEPH megaYAC library with STSs generated from the ends of cosmids RMC20C001, RMC20C30 and RMC20C028 localized RMC20C001 to each of the same three YAC clones. It was estimated, based on the size of the smallest of these YAC clones, that D20S120-D20S 183-RMC20C001-D20S480-D20S211 map into an interval of less than 1.1 Mb. D20S100 was localized 300 kb distal to D20S120 by interphase FISH and to YAC901b12 by STS mapping. The combined STS data made it possible to construct a 12 member YAC contig which spans roughly 4 Mb encompassing the 1.5 Mb amplicon and containing the loci RMC20C030-PCK1-RMC20C001-MC3R-RMC20CO26. Each YAC was mapped by FISH to confirm localization to 20q13.2 and to check for chimerism. Five clonal isolates of each YAC were sized by pulsed field gel electrophoresis (PFGE). None of the YACs are chimeric, however, several are highly unstable.

The YAC contig served as a framework from which to construct a 2 Mb P1 contig spanning the 20Q13 amplicon. P1 clones offered numerous advantages over YAC clones including (1) stability, (2) a chimeric frequency of less than 1%, (3) DNA isolation by standard miniprep procedures, (4) they make ideal FISH probes, (5) the ends can be sequenced directly, (6) engineered $\gamma\delta$ transposons carrying bidirectional primer binding sites can be integrated at any position in the cloned DNA (Strathmann *et al.*, *Proc. Natl. Acad. Sci. USA*, 88: 1247 (1991)) (7) P1 clones are the templates for sequencing the human and *Drosophila* genomes at the LBNL HGC (Palazzolo *et al.* *DOE Human Genome Program, Contractor-Grantee Workshop IV. Santa Fe, New Mexico, November 13-17 1994*).

About 90 P1 clones were isolated by screening the DuPont P1 library either by PCR or filter hybridization. For PCR based screening, more than 22 novel STSs were created by two methods. In the first method, the ends of P1 clones localized to the amplicon were sequenced, STSs developed, and the P1 library screened for walking clones. In the second approach inter-Alu PCR (Nelson *et al.*, 86: 6686-6690 (1989)) was performed on YACs spanning the amplicon and the products cloned and

sequenced for STS creation. In the filter based hybridization scheme P1 clones were obtained by performing inter-Alu PCR on YACs spanning the amplicon, radio-labeling the products and hybridizing these against filters containing a gridded array of the P1 library. Finally, to close gaps a human genomic bacterial artificial chromosome (BAC) library (Shizuya *et al.* *Proc. Natl. Acad. Sci. USA*, 89: 8794 (1992), commercially available from Research Genetics, Huntsville, Alabama, USA) was screened by PCR. These methods combined to produce more than 100 P1 and BAC clones were localized to 20q13.2 by FISH. STS content mapping, fingerprinting, and free-chromatin fish (Heiskanen *et al.*, *BioTechniques*, 17: 928 (1994)) were used to construct the 2 Mb contig shown in Figure 3.

Fine Mapping the 20q13.2 Amplicon in BT474

Clones from the 2 Mb P1 contig were used with FISH to map the level of amplification at 20q13.2 in the breast cancer cell line BT474. 35 P1 probes distributed at regular intervals along the contig were used. The resulting data indicated that the region of *highest copy number increase* in BT474 occurs between D20S100 and D20S211, an interval of approximately 1.5 Mb. P1 FISH probes, in this interval, detect an average of 50 signals per interphase nuclei in BT474, while no, or only low level amplification, was detected with the P1 clones outside this region. Thus, both the proximal and distal boundaries of the amplicon were cloned.

Fine Mapping the 20q13.2 Amplicon in Primary Tumors.

Fine mapping the amplicon in primary tumors revealed the *minimum common region of high amplification* that is of pathobiological significance. This process is analogous to screening for informative meiosis in the narrowing of genetic intervals encoding heritable disease genes. Analysis of 132 primary tumors revealed thirty-eight primary tumors that are amplified at the RMC20C001 locus. Nine of these tumors have high level amplification at the RMC20C001 locus and were further analyzed by interphase FISH with 8 P1s that span the \approx 2 Mb contig. The minimum common region of amplification was mapped to a \approx 600 kb interval flanked by P1 clones #3 and #12 with the highest level of amplification detected by P1 clone #38 corresponding to RMC20C001 (Figure 4).

The P1 and BAC clones spanning the 600 kb interval of the 20q13 amplicon are listed in Table 1 which provides a cross-reference to the DuPont P1 library described by Shepherd, *et al.*, *Proc. Natl. Acad. Sci. USA*, 92: 2629 (1994). These P1

Table 1. Cross reference to probes of the DuPont P1 library (Shepherd, *et al.*, *Proc. Natl. Acad. Sci. USA*, 92:2629 (1994) which is commercially available from Genomic Systems, St. Louis, Missouri, USA). PCR primers are illustrated for amplification of Sequence tag sites for each clone. In addition, PCR conditions (Mg concentration and annealing temperature), as well as PCR product size, is provided. Size: PCR product Size; mM MgCl: Mg concentration; Ann.: Annealing temperature; P1: P1 probe ID number; PC: DuPont Library Plate Coordinates; SCA: DuPont Library Single Clone address; SEQ-forward and SEQ-backward: forward and backward PCR primers, respectively; SEQ ID NO:-forward and SEQ ID NO:-backward: Sequence Listing SEQ ID NO: for forward and backward primers, respectively.

PRIMER NAME	SIZE (bp)	mM MgCl	Ann.	P1	PC	SCA	SEQ-forward	SEQ-backward	SEQ ID NO:- forward	SEQ ID NO:- backward
352.32	136	1.5	52	20	103 a 5	122 a e	TGGCATTGGTATCAGGTGGCTG	TGGCAGAGGGGATTTGTTG	9	10
388.13 F1/B1	201	1.5	52	17	69 b 6	821	AATCCCTCAAACCCCTGCTGTCAC	TGGGCCAACTCTGCATACT	11	12
D20S183	270	3	48	19	984	1167f	-	-	-	-
D20S211 I/2	135	1.5	52	40	12486	276h	CCGGGATAACCGAACATTG	TGCACATAAACAGCCAGC	13	14
D20S480	300	3	55	29	11914	1418f	TTGGAATCAANTGGAGCAAA	AGCTTACCCATGTGGTCC	15	16
				68	100d12	119942	GTGGTGAAACACCAATAAXTGG	AAGCAATAAACCAATAACTCG	17	18
				41	86c1	1020c	-	-	-	-
				42	10349	1232d	-	-	-	-
				67	91b2	1081b9	-	-	-	-
9X-SP6 hmF/hmB	165	1.5	55	7	31d11	370d	CAAGATCTGACCCCCGTCAATC	GACTCTTCAGGAAAGAGATCAGTG	19	20
				9	3519	416f	-	-	-	-
11S-17 F2/B4	146	3	58	11	41b1	480b	GCCATGTACCCACCTGAAAAATC	TICAGAACCCGTGCAAAATAAG	21	22
12T-17 F2/B1	153	3	58	12	42c2	493e	CCTAAAAACTTGTGGCTTAATCTA	GTCTCACAGGGAGATGTGG	23	24
28T F1/B1	219	1.5	52	74	88812	TTTGTGATGTGGCCATC	CTTCCAATCTCATCTATGAGG	25	26	
				2	12c6	137c	-	-	-	-
				25	118c11	1413c	-	-	-	-
				26	118c11	1413c	-	-	-	-
				28	118g11	1413g	GCTTGTAAAGCTCACTAGGG	CACTCTGGTAATGACCTTGTG	27	28
				25	118c11	1413c	-	-	-	-
				27	118g11	1413g	-	-	-	-
				10	36f10	429f	-	-	-	-
69S	100	3	55	69	412b5	CCTACACCATTCAACTTGG	GCGAGATGTATTTGCTACGGAAAC	29	30	
HSCOFH032 F/B	129	1.5	55	3	23c1	264c	TCTCAAACTGTCCACTCTTG	CTGCTGGGGGAGAATGG	31	32
				12 a 11	142e	-	-	-	-	-
				18	77a10	921a	-	-	-	-
60A1	191	1.5	58	36	112g8	1139g	TGTCCCTCTCTCCATCTAC	AATGCCCTCCACTCACAGGAATG	33	34
				39	34a6	401a	-	-	-	-
820F/AT T/F1/B1	175	1.5	48	15	53c7	630c	CCCTCTCACTCTCCATTGA	GGGAGAGGTGTTAGGCAAC	35	36
				16	58b9	692b	-	-	-	-

Table 2. Cross reference to probes of the BAC library. Clone # refers to the clone number provided, e.g., in Figure 4, while the plate coordinates are the plate coordinates in the Research Genetics BAC library. Size: PCR product Size; mM MgCl: Mg concentration; Ann.: Annealing temperature; BAC #: BAC probe ID number; SEQ-forward and SEQ-backward: forward and backward PCR primers, respectively; SEQ ID NO:-forward and SEQ ID NO:-backward: Sequence Listing SEQ ID NO: for forward and backward primers, respectively.

PRIMER NAME	SIZE (bp)	mM MgCl	Ann.	BAC Plate Coordinates	SEQ-forward	SEQ-backward		SEQ ID NO:- forward	SEQ ID NO:- backward
18T F1/B1	156	3	62	99 L11 plate 146	AGCAAAGCAAAGGTGGCACAC	TGACATGGAGAACACACTTC	37	38	
9S F1/B1	214	1.5	55	97 E8 plate 183	AGGTITACCAATGTGTTGG	TCTACATCCCCATTCTCTCTG	39	40	
D20S480	300	3	55	95 H15 plate 140	GTGGTGAAACCCAATAATGG	AAGCAATAAAAACCAATAACTCG	17	18	
D20S211 I/2	135	1.5	52	103 A15 plate 188	TTGGAATCAATGGAGCAAAA	AGCTTACCCAAATGTGGTCC	15	16	
				102 A1 plate 46	"	"	"	"	
11S-17 F2/B4	146	3	58	100 E4 plate 43	GCCATGTACCCACCTGAAAAATC	TCAGAACACCCGTGAGAATTAAAG	21	22	
				101 J5 plate 118	"	"	"	"	

and BAC probes are available commercially from Genetic Systems, and Research Genetics, respectively).

cDNA sequences from the 20q13 amplicon.

Exon trapping (see, e.g., Duyk *et al.*, *Proc. Natl. Acad. Sci. USA*, 87: 8995-8999 (1990) and Church *et al.*, *Nature Genetics*, 6: 98-105 (1994)) was performed on the P1 and BAC clones spanning the ≈600 kb minimum common region of amplification and has isolated more than 200 exons.

Analysis of the exons DNA sequence revealed a number of sequence similarities (85% to 96%) to partial CDNA sequences in the expressed sequence data base (dbest) and to a *S. cerevisiae* chromosome XIV open reading frame. Each P1 clone subjected to exon trapping has produced multiple exons consistent with at least a medium density of genes. Over 200 exons have been trapped and analyzed as well as 200 clones isolated by direct selection from a BT474 cDNA library. In addition a 0.6 Mb genomic interval spanning the minimal amplicon described below is being sequenced.

Exon prediction and gene modeling are carried out with XGRAIL, SORFIND, and BLAST programs. Gene fragments identified by these approaches have been analyzed by RT-PCR, Northern and Southern blots. Fifteen unique genes were identified in this way (see, Table 3 and Figure 5).

In addition two other genes ZABC1 (SEQ. ID. 9 and 10) and 1b1 (SEQ ID No. 12) were also shown to be overexpressed in a variety of different cancer cells.

Sequence information from various cDNA clones are provided below. They are as follows:

3bf4 (SEQ. ID. No. 1) - 3kb transcript with sequence identity to a tyrosine kinase gene, termed A6, disclosed in Beeler *et al.* *Mol. Cell. Biol.* 14:982-988 (1994) and WO 95/19439. These references, however, do not disclose that the gene is located in the chromosome 20 amplicon.

1b11 (SEQ. ID. No. 2) - an approximately 3.5 kb transcript whose expression shows high correlation with the copy number of the amplicon. The sequence shows no homology with sequences in the databases searched.

cc49 (SEQ. ID. No. 3) - a 6-7 kb transcript which shows homology to C2H2 zinc finger genes.

cc43 (SEQ. ID. No. 4) - an approximately 4 kb transcript which is expressed in normal tissues, but whose expression in the breast cancer cell line has not been detected.

41.1 (SEQ. ID. No. 5) - shows homology to the homeobox T shirt gene in
5 Drosophila.

GCAP (SEQ. ID. No. 6) - encodes a guanino cyclase activating protein which is involved in the biosynthesis of cyclic AMP. As explained in detail below, sequences from this gene can also be used for treatment of retinal degeneration.

1b4 (SEQ. ID. No. 7) - a serine threonine kinase.

10 20sa7 (SEQ. ID. No. 8) - a homolog of the rat gene, BEM-1.

In addition, the entire nucleotide sequence is provided for ZABC-1.

ZABC-1 stands for zinc finger amplified in breast cancer. This gene maps to the core of the 20q13.2 amplicon and is overexpressed in primary tumors and breast cancer cell lines having 20q13.2 amplification. The genomic sequence (SEQ. ID. No. 9) includes roughly 15 2kb of the promoter region. SEQ ID. No. 10 provides the cDNA sequence derived open reading frame and SEQ ID. No. 11 provides the predicted protein sequence. Zinc finger containing genes are often transcription factors that function to modulate the expression of down stream genes. Several known oncogenes are in fact zinc finger containing genes.

20 This invention also provides the full length cDNA sequence for a cDNA designated 1b1 (SEQ. ID. No. 12) which is also overexpressed in numerous breast cancer cell lines and some primary tumors.

SEQ ID NO: 13 provides sequence from a genomic clone which is similar to known rat and mouse cyclophilin cDNAs. Rat Cyclophilin nucleic acids (*e.g.*, 25 cDNAs) are known; *see*, GenBank™ under accession No. M19533; Mouse Cyclophilin nucleic acids (*e.g.*, cDNAs) are known; *see*, GenBank™ under accession No. 50620. Accordingly, SEQ ID NO: 13 is a putative human cyclophilin gene. The sequence is also associated with amplified sequences from 20q13, and can be used as a probe or 30 probe hybridization target to detect DNA amplification, or RNA overexpression of the corresponding gene.

Table 3. Gene fragments identified by exon trapping and analyzed by RT-PCR,
Northern and Southern blots.

Map #	Gene ID	Transcript Size (kb)	EST Identity (>95 %)	Cloned Sequence (kb)	Protein Homologies	Map Location
5	1	20sa7	-	Yes	3	PTP
	2	1b11	3.5	No	1.5	novel
	3	200.1	-	-	-	-
	4	132.1	-	-	-	novel
	5	132.2	-	-	-	132
10	6	3bf4	3	Yes	3	PTK
	7	7.1	-	-	-	-
	8	7.2	2.4	-	-	-
	9	cc49	7, 4	Yes	3.6	Kruppel
	10	cc43	1.4	Yes	1.8	hypothetical yeast protein
15	11	et1807	2.5	Yes	0.7	novel
	12	et2106	None	Yes	-	-
	13	41.1	detected	Yes	3	homeotic gene
	14	67.1	7, 8, 11	Yes	2Kb	cGMP reg.
	15	67.2	-	Yes	-	protein
20q13 Amplicon Proteins						

25

As indicated above, this invention also provides for proteins encoded by nucleic acid sequences in the 20q13 amplicon (*e.g.*, SEQ. ID. Nos: 1-10 and 12-13) and subsequences more preferably subsequences of at least 10 amino acids, preferably of at least 20 amino acids, and most preferably of at least 30 amino acids in length.

Particularly preferred subsequences are epitopes specific to the 20q13 proteins more preferably epitopes specific to the ZABC1 and 1b1 proteins. Such proteins include, but

are not limited to isolated polypeptides comprising at least 10 contiguous amino acids from a polypeptide encoded by the nucleic acids of SEQ. ID No. 1-10 and 12-13 or from the polypeptide of SEQ. ID. No. 11 wherein the polypeptide, when presented as an immunogen, elicits the production of an antibody which specifically binds to a
5 polypeptide selected from the group consisting of a polypeptide encoded by the nucleic acids of SEQ. ID No. 1-10 and 12-13 or from the polypeptide of SEQ. ID. No. 11 and the polypeptide does not bind to antisera raised against a polypeptide selected from the group consisting of a polypeptide encoded by the nucleic acids of SEQ. ID No. 1-10 and 12 or from the polypeptide of SEQ. ID. No. 11 which has been fully immunosorbed with
10 a polypeptide selected from the group consisting of a polypeptide encoded by the nucleic acids of SEQ. ID No. 1-10 and 12-13 or from the polypeptide of SEQ. ID. No. 11.

A protein that specifically binds to or that is specifically immunoreactive with an antibody generated against a defined immunogen, such as an immunogen consisting of the amino acid sequence of SEQ ID NO 11 is determined in an
15 immunoassay. The immunoassay uses a polyclonal antiserum which was raised to the protein of SEQ ID NO 11 (the immunogenic polypeptide). This antiserum is selected to have low crossreactivity against other similar known polypeptides and any such crossreactivity is removed by immunoabsorption prior to use in the immunoassay (e.g., by immunosorption of the antisera with the related polypeptide).

20 In order to produce antisera for use in an immunoassay, the polypeptide e.g., the polypeptide of SEQ ID NO 11 is isolated as described herein. For example, recombinant protein can be produced in a mammalian or other eukaryotic cell line. An inbred strain of mice is immunized with the protein of SEQ ID NO 11 using a standard adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol (see
25 Harlow and Lane, *supra*). Alternatively, a synthetic polypeptide derived from the sequences disclosed herein and conjugated to a carrier protein is used as an immunogen. Polyclonal sera are collected and titered against the immunogenic polypeptide in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of 10^4 or greater are selected and
30 tested for their cross reactivity against known polypeptides using a competitive binding immunoassay such as the one described in Harlow and Lane, *supra*, at pages 570-573. Preferably more than one known polypeptide is used in this determination in conjunction with the immunogenic polypeptide.

The known polypeptides can be produced as recombinant proteins and isolated using standard molecular biology and protein chemistry techniques as described herein.

Immunoassays in the competitive binding format are used for crossreactivity determinations. For example, the immunogenic polypeptide is immobilized to a solid support. Proteins added to the assay compete with the binding of the antisera to the immobilized antigen. The ability of the proteins to compete with the binding of the antisera to the immobilized protein is compared to the immunogenic polypeptide. The percent crossreactivity for the protein is calculated, using standard calculations. Those antisera with less than 10% crossreactivity to known polypeptides are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorption with known polypeptide.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described herein to compare a "target" polypeptide to the immunogenic polypeptide. To make this comparison, the two polypeptides are each assayed at a wide range of concentrations and the amount of each polypeptide required to inhibit 50% of the binding of the antisera to the immobilized protein is determined using standard techniques. If the amount of the target polypeptide required is less than twice the amount of the immunogenic polypeptide that is required, then the target polypeptide is said to specifically bind to an antibody generated to the immunogenic protein. As a final determination of specificity, the pooled antisera is fully immunosorbed with the immunogenic polypeptide until no binding to the polypeptide used in the immunosorption is detectable. The fully immunosorbed antisera is then tested for reactivity with the test polypeptide. If no reactivity is observed, then the test polypeptide is specifically bound by the antisera elicited by the immunogenic protein.

Similarly, in a reciprocal experiment, the pooled antisera is immunosorbed with the test polypeptide. If the antisera which remains after the immunosorption does not bind to the immunogenic polypeptide (*i.e.*, the polypeptide of SEQ ID NO: 11 used to elicit the antisera) then the test polypeptide is specifically bound by the antisera elicited by the immunogenic peptide.

Detection of 20q13 Abnormalities.

One of skill in the art will appreciate that the clones and sequence information provided herein can be used to detect amplifications, or other chromosomal

abnormalities, at 20q13 in a biological sample. Generally the methods involve hybridization of probes that specifically bind one or more nucleic acid sequences of the target amplicon with nucleic acids present in a biological sample or derived from a biological sample.

5 As used herein, a biological sample is a sample of biological tissue or fluid containing cells desired to be screened for chromosomal abnormalities (*e.g.* amplifications of deletions). In a preferred embodiment, the biological sample is a cell or tissue suspected of being cancerous (transformed). Methods of isolating biological samples are well known to those of skill in the art and include, but are not limited to, 10 aspirations, tissue sections, needle biopsies, and the like. Frequently the sample will be a "clinical sample" which is a sample derived from a patient. It will be recognized that the term "sample" also includes supernatant (containing cells) or the cells themselves from cell cultures, cells from tissue culture and other media in which it may be desirable to detect chromosomal abnormalities.

15 In a preferred embodiment, a biological sample is prepared by depositing cells, either as single cell suspensions or as tissue preparation, on solid supports such as glass slides and fixed by choosing a fixative which provides the best spatial resolution of the cells and the optimal hybridization efficiency.

Making Probes

20 Any of the P1 probes listed in Table 1, the BAC probes listed in Table 2, or the cDNAs disclosed here are suitable for use in detecting the 20q13 amplicon. Methods of preparing probes are well known to those of skill in the art (*see, e.g.* Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual* (2nd ed.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989) or *Current Protocols in Molecular Biology*, F. 25 Ausubel *et al.*, ed. Greene Publishing and Wiley-Interscience, New York (1987))

Given the strategy for making the nucleic acids of the present invention, one of skill can construct a variety of vectors and nucleic acid clones containing functionally equivalent nucleic acids. Cloning methodologies to accomplish these ends, and sequencing methods to verify the sequence of nucleic acids are well known in the 30 art. Examples of appropriate cloning and sequencing techniques, and instructions sufficient to direct persons of skill through many cloning exercises are found in Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology* volume 152 Academic Press, Inc., San Diego, CA (Berger); Sambrook *et al.* (1989) *Molecular*

Cloning - A Laboratory Manual (2nd ed.) Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY, (Sambrook); and *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1994 Supplement) (Ausubel).

5 Product information from manufacturers of biological reagents and experimental equipment also provide information useful in known biological methods. Such manufacturers include the SIGMA chemical company (Saint Louis, MO), R&D systems (Minneapolis, MN), Pharmacia LKB Biotechnology (Piscataway, NJ), CLONTECH Laboratories, Inc. (Palo Alto, CA), Chem Genes Corp., Aldrich Chemical Company (Milwaukee, WI), Glen Research, Inc., GIBCO BRL Life Technologies, Inc. (Gaithersberg, MD), Fluka Chemica-Biochemika Analytika (Fluka Chemie AG, Buchs, Switzerland), Invitrogen, San Diego, CA, and Applied Biosystems (Foster City, CA), as well as many other commercial sources known to one of skill.

10 The nucleic acids provided by this invention, whether RNA, cDNA, genomic DNA, or a hybrid of the various combinations, are isolated from biological sources or synthesized *in vitro*. The nucleic acids and vectors of the invention are present in transformed or transfected whole cells, in transformed or transfected cell lysates, or in a partially purified or substantially pure form.

15 *In vitro* amplification techniques suitable for amplifying sequences to provide a nucleic acid, or for subsequent analysis, sequencing or subcloning are known. Examples of techniques sufficient to direct persons of skill through such *in vitro* amplification methods, including the polymerase chain reaction (PCR) the ligase chain reaction (LCR), Q β -replicase amplification and other RNA polymerase mediated techniques (*e.g.*, NASBA) are found in Berger, Sambrook, and Ausubel, as well as 20 Mullis *et al.*, (1987) U.S. Patent No. 4,683,202; *PCR Protocols A Guide to Methods and Applications* (Innis *et al.* eds) Academic Press Inc. San Diego, CA (1990) (Innis); Arnheim & Levinson (October 1, 1990) *C&EN* 36-47; *The Journal Of NIH Research* (1991) 3, 81-94; (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86, 1173; Guatelli *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87, 1874; Lomell *et al.* (1989) *J. Clin. Chem* 35, 25 1826; Landegren *et al.*, (1988) *Science* 241, 1077-1080; Van Brunt (1990) *Biotechnology* 8, 291-294; Wu and Wallace, (1989) *Gene* 4, 560; Barringer *et al.* (1990) *Gene* 89, 117, 30 and Sooknanan and Malek (1995) *Biotechnology* 13: 563-564. Improved methods of cloning *in vitro* amplified nucleic acids are described in Wallace *et al.*, U.S. Pat. No.

5,426,039. Improved methods of amplifying large nucleic acids are summarized in Cheng *et al.* (1994) *Nature* 369: 684-685 and the references therein.

Nucleic Acids (*e.g.*, oligonucleotides) for *in vitro* amplification methods or for use as gene probes, for example, are typically chemically synthesized according to 5 the solid phase phosphoramidite triester method described by Beaucage and Caruthers (1981), *Tetrahedron Letts.*, 22(20):1859-1862, *e.g.*, using an automated synthesizer, as described in Needham-VanDevanter *et al.* (1984) *Nucleic Acids Res.*, 12:6159-6168.

Purification of oligonucleotides, where necessary, is typically performed by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson and 10 Regnier (1983) *J. Chrom.* 255:137-149. The sequence of the synthetic oligonucleotides can be verified using the chemical degradation method of Maxam and Gilbert (1980) in Grossman and Moldave (eds.) Academic Press, New York, *Methods in Enzymology* 65:499-560.

The probes are most easily prepared by combining and labeling one or 15 more of the constructs listed in Tables 1 and 2. Prior to use, the constructs are fragmented to provide smaller nucleic acid fragments that easily penetrate the cell and hybridize to the target nucleic acid. Fragmentation can be by any of a number of methods well known to those of skill in the art. Preferred methods include treatment with a restriction enzyme to selectively cleave the molecules, or alternatively to briefly heat 20 the nucleic acids in the presence of Mg²⁺. Probes are preferably fragmented to an average fragment length ranging from about 50 bp to about 2000 bp, more preferably from about 100 bp to about 1000 bp and most preferably from about 150 bp to about 500 bp.

Alternatively, probes can be produced by amplifying (*e.g.* via PCR) 25 selected subsequences from the 20q13 amplicon disclosed herein. The sequences provided herein permit one of skill to select primers that amplify sequences from one or more exons located within the 20q13 amplicon.

Particularly preferred probes include nucleic acids from probes 38, 40, and 30 79, which corresponds to RMC20C001. In addition, the cDNAs are particularly useful for identifying cells that have increased expression of the corresponding genes, using for instance, Northern blot analysis.

One of skill will appreciate that using the sequence information and clones provided herein, one of skill in the art can isolate the same or similar probes from other human genomic libraries using routine methods (*e.g.* Southern or Northern Blots).

Similarly, the polypeptides of the invention can be synthetically prepared in a wide variety of well-known ways. For instance, polypeptides of relatively short length can be synthesized in solution or on a solid support in accordance with conventional techniques. *See, e.g.*, Merrifield (1963) *J. Am. Chem. Soc.* 85:2149-2154. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. *See, e.g.*, Stewart and Young (1984) *Solid Phase Peptide Synthesis*, 2d. ed., Pierce Chemical Co. As described in more detail herein, the polypeptide of the invention are most preferably made using recombinant techniques, *e.g.*, by expressing the polypeptides in host cells and purifying the expressed proteins.

In a preferred embodiment, the polypeptides, or subsequences thereof, are synthesized using recombinant DNA methodology. Generally this involves creating a DNA sequence that encodes the protein, through recombinant, synthetic, or *in vitro* amplification techniques, placing the DNA in an expression cassette under the control of a particular promoter, expressing the protein in a host cell, isolating the expressed protein and, if required, renaturing the protein.

Labeling Probes

Methods of labeling nucleic acids are well known to those of skill in the art. Preferred labels are those that are suitable for use in *in situ* hybridization. The nucleic acid probes may be detectably labeled prior to the hybridization reaction. Alternatively, a detectable label which binds to the hybridization product may be used. Such detectable labels include any material having a detectable physical or chemical property and have been well-developed in the field of immunoassays.

As used herein, a "label" is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Useful labels in the present invention include radioactive labels (*e.g.* ^{32}P , ^{125}I , ^{14}C , ^3H , and ^{35}S), fluorescent dyes (*e.g.* fluorescein, rhodamine, Texas Red, *etc.*), electron-dense reagents (*e.g.* gold), enzymes (as commonly used in an ELISA), colorimetric labels (*e.g.* colloidal gold), magnetic labels (*e.g.* DynabeadsTM), and the like. Examples of labels which are not directly detected but are detected through the use of directly detectable label include

biotin and dioxigenin as well as haptens and proteins for which labeled antisera or monoclonal antibodies are available.

The particular label used is not critical to the present invention, so long as it does not interfere with the *in situ* hybridization of the stain. However, stains directly labeled with fluorescent labels (*e.g.* fluorescein-12-dUTP, Texas Red-5-dUTP, *etc.*) are preferred for chromosome hybridization.

A direct labeled probe, as used herein, is a probe to which a detectable label is attached. Because the direct label is already attached to the probe, no subsequent steps are required to associate the probe with the detectable label. In contrast, an indirect labeled probe is one which bears a moiety to which a detectable label is subsequently bound, typically after the probe is hybridized with the target nucleic acid.

In addition the label must be detectable in as low copy number as possible thereby maximizing the sensitivity of the assay and yet be detectable above any background signal. Finally, a label must be chosen that provides a highly localized signal thereby providing a high degree of spatial resolution when physically mapping the stain against the chromosome. Particularly preferred fluorescent labels include fluorescein-12-dUTP and Texas Red-5-dUTP.

The labels may be coupled to the probes in a variety of means known to those of skill in the art. In a preferred embodiment the nucleic acid probes will be labeled using nick translation or random primer extension (Rigby, *et al.* *J. Mol. Biol.*, 113: 237 (1977) or Sambrook, *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1985)).

One of skill in the art will appreciate that the probes of this invention need not be absolutely specific for the targeted 20q13 region of the genome. Rather, the probes are intended to produce "staining contrast". "Contrast" is quantified by the ratio of the probe intensity of the target region of the genome to that of the other portions of the genome. For example, a DNA library produced by cloning a particular chromosome (*e.g.* chromosome 7) can be used as a stain capable of staining the entire chromosome. The library contains both sequences found only on that chromosome, and sequences shared with other chromosomes. Roughly half the chromosomal DNA falls into each class. If hybridization of the whole library were capable of saturating all of the binding sites on the target chromosome, the target chromosome would be twice as bright (contrast ratio of 2) as the other chromosomes since it would contain signal from the both

the specific and the shared sequences in the stain, whereas the other chromosomes would only be stained by the shared sequences. Thus, only a modest decrease in hybridization of the shared sequences in the stain would substantially enhance the contrast. Thus contaminating sequences which only hybridize to non-targeted sequences, for example, 5 impurities in a library, can be tolerated in the stain to the extent that the sequences do not reduce the staining contrast below useful levels.

Detecting the 20q13 Amplicon.

As explained above, detection of amplification in the 20q13 amplicon is 10 indicative of the presence and/or prognosis of a large number of cancers. These include, but are not limited to breast, ovary, bladder, head and neck, and colon.

In a preferred embodiment, a 20q13 amplification is detected through the hybridization of a probe of this invention to a target nucleic acid (*e.g.* a chromosomal sample) in which it is desired to screen for the amplification. Suitable hybridization 15 formats are well known to those of skill in the art and include, but are not limited to, variations of Southern Blots, *in situ* hybridization and quantitative amplification methods such as quantitative PCR (*see, e.g.* Sambrook, *supra.*, Kallioniemi *et al.*, *Proc. Natl Acad Sci USA*, 89: 5321-5325 (1992), and *PCR Protocols, A Guide to Methods and Applications*, Innis *et al.*, Academic Press, Inc. N.Y., (1990)).

In situ Hybridization.

In a preferred embodiment, the 20q13 amplicon is identified using *in situ* hybridization. Generally, *in situ* hybridization comprises the following major steps: (1) fixation of tissue or biological structure to analyzed; (2) prehybridization treatment of the 25 biological structure to increase accessibility of target DNA, and to reduce nonspecific binding; (3) hybridization of the mixture of nucleic acids to the nucleic acid in the biological structure or tissue; (4) posthybridization washes to remove nucleic acid fragments not bound in the hybridization and (5) detection of the hybridized nucleic acid fragments. The reagent used in each of these steps and their conditions for use vary depending on the particular application.

30 In some applications it is necessary to block the hybridization capacity of repetitive sequences. In this case, human genomic DNA is used as an agent to block such hybridization. The preferred size range is from about 200 bp to about 1000 bases,

more preferably between about 400 to about 800 bp for double stranded, nick translated nucleic acids.

Hybridization protocols for the particular applications disclosed here are described in Pinkel *et al.* *Proc. Natl. Acad. Sci. USA*, 85: 9138-9142 (1988) and in EPO Pub. No. 430,402. Suitable hybridization protocols can also be found in *Methods of Molecular Biology Vol. 33: In Situ Hybridization Protocols*, K.H.A. Choo, ed., Humana Press, Totowa, New Jersey, (1994). In a particularly preferred embodiment, the hybridization protocol of Kallioniemi *et al.*, *Proc. Natl Acad Sci USA*, 89: 5321-5325 (1992) is used.

Typically, it is desirable to use dual color FISH, in which two probes are utilized, each labelled by a different fluorescent dye. A test probe that hybridizes to the region of interest is labelled with one dye, and a control probe that hybridizes to a different region is labelled with a second dye. A nucleic acid that hybridizes to a stable portion of the chromosome of interest, such as the centromere region, is often most useful as the control probe. In this way, differences between efficiency of hybridization from sample to sample can be accounted for.

The FISH methods for detecting chromosomal abnormalities can be performed on nanogram quantities of the subject nucleic acids. Paraffin embedded tumor sections can be used, as can fresh or frozen material. Because FISH can be applied to the limited material, touch preparations prepared from uncultured primary tumors can also be used (*see, e.g.*, Kallioniemi, A. *et al.*, *Cytogenet. Cell Genet.* 60: 190-193 (1992)). For instance, small biopsy tissue samples from tumors can be used for touch preparations (*see, e.g.*, Kallioniemi, A. *et al.*, *Cytogenet. Cell Genet.* 60: 190-193 (1992)). Small numbers of cells obtained from aspiration biopsy or cells in bodily fluids (*e.g.*, blood, urine, sputum and the like) can also be analyzed. For prenatal diagnosis, appropriate samples will include amniotic fluid and the like.

Southern Blots

In a Southern Blot, a genomic or cDNA (typically fragmented and separated on an electrophoretic gel) is hybridized to a probe specific for the target region. Comparison of the intensity of the hybridization signal from the probe for the target region (*e.g.*, 20q13) with the signal from a probe directed to a control (non amplified) such as centromeric DNA, provides an estimate of the relative copy number of the target nucleic acid.

Detecting Mutations in Genes from the 20q13 Amplicon

The cDNA sequences disclosed here can also be used for detecting mutations (*e.g.*, substitutions, insertions, and deletions) within the corresponding endogenous genes. One of skill will recognize that the nucleic acid hybridization techniques generally described above can be adapted to detect such much mutations. For instance, oligonucleotide probes that distinguish between mutant and wild-type forms of the target gene can be used in standard hybridization assays. In some embodiments, amplification (*e.g.*, using PCR) can be used to increase copy number of the target sequence prior to hybridization.

Assays for detecting 20q13 amplicon proteins.

As indicated above, this invention identifies protein products of genes in the 20q13 amplicon that are associated with various cancers. In particular, it was shown that 20q13 proteins were overexpressed in various cancers. The presence or absence and/or level of expression of 20q13 proteins can be indicative of the presence, absence, or extent of a cancer. Thus, 20q13 proteins can provide useful diagnostic markers.

The 20q13 amplicon proteins (*e.g.*, ZABC1 or 1b1) can be detected and quantified by any of a number of means well known to those of skill in the art. These may include analytic biochemical methods such as electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like, or various immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassay(RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, western blotting, and the like.

In one preferred embodiment, the 20q13 amplicon proteins are detected in an electrophoretic protein separation such as a one dimensional or two-dimensional electrophoresis, while in a most preferred embodiment, the 20q13 amplicon proteins are detected using an immunoassay.

As used herein, an immunoassay is an assay that utilizes an antibody to specifically bind to the analyte (*e.g.*, ZABC1 or 1b1 proteins). The immunoassay is thus characterized by detection of specific binding of a 20q13 amplicon protein to an anti-20q13 amplicon antibody (*e.g.*, anti-ZABC1 or anti-1b1) as opposed to the use of other physical or chemical properties to isolate, target, and quantify the analyte.

The collection of biological sample and subsequent testing for 20q13 amplicon protein(s) is discussed in more detail below.

A) Sample Collection and Processing

The 20q13 amplicon proteins are preferably quantified in a biological sample derived from a mammal, more preferably from a human patient or from a porcine, murine, feline, canine, or bovine. As used herein, a biological sample is a sample of biological tissue or fluid that contains a 20q13 amplicon protein concentration that may be correlated with a 20q13 amplification. Particularly preferred biological samples include, but are not limited to biological fluids such as blood or urine, or tissue samples including, but not limited to tissue biopsy (*e.g.*, needle biopsy) samples.

The biological sample may be pretreated as necessary by dilution in an appropriate buffer solution or concentrated, if desired. Any of a number of standard aqueous buffer solutions, employing one of a variety of buffers, such as phosphate, Tris, or the like, at physiological pH can be used.

B) Electrophoretic Assays.

As indicated above, the presence or absence of 20q13 amplicon proteins in a biological tissue may be determined using electrophoretic methods. Means of detecting proteins using electrophoretic techniques are well known to those of skill in the art (*see generally*, R. Scopes (1982) *Protein Purification*, Springer-Verlag, N.Y.; Deutscher, (1990) *Methods in Enzymology Vol. 182: Guide to Protein Purification.*, Academic Press, Inc., N.Y.). In a preferred embodiment, the 20q13 amplicon proteins are detected using one-dimensional or two-dimensional electrophoresis. A particularly preferred two-dimensional electrophoresis separation relies on isoelectric focusing (IEF) in immobilized pH gradients for one dimension and polyacrylamide gels for the second dimension. Such assays are described in the cited references and by Patton *et al.* (1990) *Biotechniques* 8: 518.

C) Immunological Binding Assays.

In a preferred embodiment, the 20q13 amplicon are detected and/or quantified using any of a number of well recognized immunological binding assays (*see, e.g.*, U.S. Patents 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general immunoassays, see also *Methods in Cell Biology Volume 37: Antibodies in Cell Biology*, Asai, ed. Academic Press, Inc. New York (1993); *Basic and Clinical Immunology* 7th Edition, Stites & Terr, eds. (1991).

Immunological binding assays (or immunoassays) typically utilize a “capture agent” to specifically bind to and often immobilize the analyte (in this case 20q13 amplicon). The capture agent is a moiety that specifically binds to the analyte. In a preferred embodiment, the capture agent is an antibody that specifically binds 20q13 amplicon protein(s).

The antibody (*e.g.*, anti-ZABC1 or anti-1b1) may be produced by any of a number of means well known to those of skill in the art (*see, e.g.* *Methods in Cell Biology Volume 37: Antibodies in Cell Biology*, Asai, ed. Academic Press, Inc. New York (1993); and *Basic and Clinical Immunology* 7th Edition, Stites & Terr, eds.

(1991)). The antibody may be a whole antibody or an antibody fragment. It may be polyclonal or monoclonal, and it may be produced by challenging an organism (*e.g.* mouse, rat, rabbit, *etc.*) with a 20q13 amplicon protein or an epitope derived therefrom. Alternatively, the antibody may be produced *de novo* using recombinant DNA methodology. The antibody can also be selected from a phage display library screened against 20q13 amplicon (*see, e.g.* Vaughan *et al.* (1996) *Nature Biotechnology*, 14: 309-314 and references therein).

Immunoassays also often utilize a labeling agent to specifically bind to and label the binding complex formed by the capture agent and the analyte. The labeling agent may itself be one of the moieties comprising the antibody/analyte complex. Thus, the labeling agent may be a labeled 20q13 amplicon protein or a labeled anti-20q13 amplicon antibody. Alternatively, the labeling agent may be a third moiety, such as another antibody, that specifically binds to the antibody/20q13 amplicon protein complex.

In a preferred embodiment, the labeling agent is a second human 20q13 amplicon protein antibody bearing a label. Alternatively, the second 20q13 amplicon protein antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second can be modified with a detectable moiety, such as biotin, to which a third labeled molecule can specifically bind, such as enzyme-labeled streptavidin.

Other proteins capable of specifically binding immunoglobulin constant regions, such as protein A or protein G may also be used as the label agent. These proteins are normal constituents of the cell walls of streptococcal bacteria. They exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a

variety of species. See, generally Kronval, *et al.*, *J. Immunol.*, 111:1401-1406 (1973), and Akerstrom, *et al.*, *J. Immunol.*, 135:2589-2542 (1985).

Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, preferably from about 5 minutes to about 24 hours. However, the 5 incubation time will depend upon the assay format, analyte, volume of solution, concentrations, and the like. Usually, the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10°C to 40°C.

1) Non-Competitive Assay Formats.

Immunoassays for detecting 20q13 amplicon proteins may be either competitive or noncompetitive. Noncompetitive immunoassays are assays in which the amount of captured analyte (in this case 20q13 amplicon) is directly measured. In one preferred "sandwich" assay, for example, the capture agent (anti-20q13 amplicon protein antibodies) can be bound directly to a solid substrate where they are immobilized. These immobilized antibodies then capture 20q13 amplicon protein present in the test sample. The 20q13 amplicon protein thus immobilized is then bound by a labeling agent, such as a second human 20q13 amplicon protein antibody bearing a label. Alternatively, the 15 second 20q13 amplicon protein antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second can be modified with a detectable moiety, such as biotin, to which a third labeled molecule can specifically bind, such as enzyme-labeled streptavidin.

2. Competitive assay formats.

In competitive assays, the amount of analyte (20q13 amplicon protein) present in the sample is measured indirectly by measuring the amount of an added (exogenous) analyte (20q13 amplicon proteins such as ZABC1 or 1b1 protein) displaced (or competed away) from a capture agent (*e.g.*, anti-ZABC1 or anti-1b1 antibody) by the analyte present in the sample. In one competitive assay, a known amount of, in this 20 case, 20q13 amplicon protein is added to the sample and the sample is then contacted with a capture agent, in this case an antibody that specifically binds 20q13 amplicon protein. The amount of 20q13 amplicon protein bound to the antibody is inversely proportional to the concentration of 20q13 amplicon protein present in the sample.

In a particularly preferred embodiment, the anti-20q13 protein antibody is immobilized on a solid substrate. The amount of 20q13 amplicon protein bound to the antibody may be determined either by measuring the amount of 20q13 amplicon present in an 20q13 amplicon protein/antibody complex, or alternatively by measuring the amount of remaining uncomplexed 20q13 amplicon protein. The amount of 20q13 amplicon protein may be detected by providing a labeled 20q13 amplicon protein.

A hapten inhibition assay is another preferred competitive assay. In this assay a known analyte, in this case 20q13 amplicon protein is immobilized on a solid substrate. A known amount of anti-20q13 amplicon protein antibody is added to the sample, and the sample is then contacted with the immobilized 20q13 amplicon protein. In this case, the amount of anti-20q13 amplicon protein antibody bound to the immobilized 20q13 amplicon protein is inversely proportional to the amount of 20q13 amplicon protein present in the sample. Again the amount of immobilized antibody may be detected by detecting either the immobilized fraction of antibody or the fraction of the antibody that remains in solution. Detection may be direct where the antibody is labeled or indirect by the subsequent addition of a labeled moiety that specifically binds to the antibody as described above.

3. Other Assay Formats

In a particularly preferred embodiment, Western blot (immunoblot) analysis is used to detect and quantify the presence of 20q13 amplicon protein in the sample. The technique generally comprises separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind 20q13 amplicon protein. The anti-20q13 amplicon protein antibodies specifically bind to 20q13 amplicon protein on the solid support. These antibodies may be directly labeled or alternatively may be subsequently detected using labeled antibodies (e.g., labeled sheep anti-mouse antibodies) that specifically bind to the anti-20q13 amplicon protein.

Other assay formats include liposome immunoassays (LIA), which use liposomes designed to bind specific molecules (e.g., antibodies) and release encapsulated reagents or markers. The released chemicals are then detected according to standard techniques (see, Monroe *et al.* (1986) *Amer. Clin. Prod. Rev.* 5:34-41).

D) Reduction of Non-Specific Binding.

One of skill in the art will appreciate that it is often desirable to reduce non-specific binding in immunoassays. Particularly, where the assay involves an antigen or antibody immobilized on a solid substrate it is desirable to minimize the amount of non-specific binding to the substrate. Means of reducing such non-specific binding are well known to those of skill in the art. Typically, this involves coating the substrate with a proteinaceous composition. In particular, protein compositions such as bovine serum albumin (BSA), nonfat powdered milk, and gelatin are widely used with powdered milk being most preferred.

E) Labels.

The particular label or detectable group used in the assay is not a critical aspect of the invention, so long as it does not significantly interfere with the specific binding of the antibody used in the assay. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of immunoassays and, in general, most any label useful in such methods can be applied to the present invention. Thus, a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include magnetic beads (*e.g.* DynabeadsTM), fluorescent dyes (*e.g.*, fluorescein isothiocyanate, texas red, rhodamine, and the like), radiolabels (*e.g.*, ³H, ¹²⁵I, ³⁵S, ¹⁴C, or ³²P), enzymes (*e.g.*, horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic (*e.g.* polystyrene, polypropylene, latex, *etc.*) beads.

The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. As indicated above, a wide variety of labels may be used, with the choice of label depending on sensitivity required, ease of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions.

Non-radioactive labels are often attached by indirect means. Generally, a ligand molecule (*e.g.*, biotin) is covalently bound to the molecule. The ligand then binds to an anti-ligand (*e.g.*, streptavidin) molecule which is either inherently detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent compound, or a chemiluminescent compound. A number of ligands and anti-ligands can be used. Where a ligand has a natural anti-ligand, for example, biotin, thyroxine, and

cortisol, it can be used in conjunction with the labeled, naturally occurring anti-ligands. Alternatively, any haptic or antigenic compound can be used in combination with an antibody.

The molecules can also be conjugated directly to signal generating compounds, *e.g.*, by conjugation with an enzyme or fluorophore. Enzymes of interest as labels will primarily be hydrolases, particularly phosphatases, esterases and glycosidases, or oxidoreductases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, *etc.* Chemiluminescent compounds include luciferin, and 2,3-dihydrophthalazinediones, *e.g.*, luminol. For a review of various labeling or signal producing systems which may be used, see, U.S. Patent No. 4,391,904).

Means of detecting labels are well known to those of skill in the art. Thus, for example, where the label is a radioactive label, means for detection include a scintillation counter or photographic film as in autoradiography. Where the label is a fluorescent label, it may be detected by exciting the fluorochrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence may be detected visually, by means of photographic film, by the use of electronic detectors such as charge coupled devices (CCDs) or photomultipliers and the like. Similarly, enzymatic labels may be detected by providing the appropriate substrates for the enzyme and detecting the resulting reaction product. Finally simple colorimetric labels may be detected simply by observing the color associated with the label. Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color of the bead.

Some assay formats do not require the use of labeled components. For instance, agglutination assays can be used to detect the presence of the target antibodies. In this case, antigen-coated particles are agglutinated by samples comprising the target antibodies. In this format, none of the components need be labeled and the presence of the target antibody is detected by simple visual inspection.

G) Substrates.

As mentioned above, depending upon the assay, various components, including the antigen, target antibody, or anti-human antibody, may be bound to a solid surface. Many methods for immobilizing biomolecules to a variety of solid surfaces are known in the art. For instance, the solid surface may be a membrane (*e.g.*,

nitrocellulose), a microtiter dish (*e.g.*, PVC, polypropylene, or polystyrene), a test tube (glass or plastic), a dipstick (*e.g.* glass, PVC, polypropylene, polystyrene, latex, and the like), a microcentrifuge tube, or a glass or plastic bead. The desired component may be covalently bound or noncovalently attached through nonspecific bonding.

5 A wide variety of organic and inorganic polymers, both natural and synthetic may be employed as the material for the solid surface. Illustrative polymers include polyethylene, polypropylene, poly(4-methylbutene), polystyrene, polymethacrylate, poly(ethylene terephthalate), rayon, nylon, poly(vinyl butyrate), polyvinylidene difluoride (PVDF), silicones, polyformaldehyde, cellulose, cellulose acetate, nitrocellulose, and the like. Other materials which may be employed, include paper, glasses, ceramics, metals, metalloids, semiconductive materials, cements or the like. In addition, are included substances that form gels, such as proteins (*e.g.*, gelatins), lipopolysaccharides, silicates, agarose and polyacrylamides can be used. Polymers which form several aqueous phases, such as dextrans, polyalkylene glycols or

10 surfactants, such as phospholipids, long chain (12-24 carbon atoms) alkyl ammonium salts and the like are also suitable. Where the solid surface is porous, various pore sizes may be employed depending upon the nature of the system.

15

In preparing the surface, a plurality of different materials may be employed, particularly as laminates, to obtain various properties. For example, protein coatings, such as gelatin can be used to avoid non-specific binding, simplify covalent conjugation, enhance signal detection or the like.

20 If covalent bonding between a compound and the surface is desired, the surface will usually be polyfunctional or be capable of being polyfunctionalized. Functional groups which may be present on the surface and used for linking can include carboxylic acids, aldehydes, amino groups, cyano groups, ethylenic groups, hydroxyl groups, mercapto groups and the like. The manner of linking a wide variety of compounds to various surfaces is well known and is amply illustrated in the literature. See, for example, *Immobilized Enzymes*, Ichiro Chibata, Halsted Press, New York, 1978, and Cuatrecasas (1970) *J. Biol. Chem.* 245 3059).

25

30 In addition to covalent bonding, various methods for noncovalently binding an assay component can be used. Noncovalent binding is typically nonspecific absorption of a compound to the surface. Typically, the surface is blocked with a second compound to prevent nonspecific binding of labeled assay components. Alternatively,

the surface is designed such that it nonspecifically binds one component but does not significantly bind another. For example, a surface bearing a lectin such as Concanavalin A will bind a carbohydrate containing compound but not a labeled protein that lacks glycosylation. Various solid surfaces for use in noncovalent attachment of assay components are reviewed in U.S. Patent Nos. 4,447,576 and 4,254,082.

5

Kits Containing 20q13 Amplicon Probes.

This invention also provides diagnostic kits for the detection of chromosomal abnormalities at 20q13. In a preferred embodiment, the kits include one or more probes to the 20q13 amplicon and/or antibodies to a 20q13 amplicon (*e.g.*, anti-ZABC1 *or* anti-*Ib1*) described herein. The kits can additionally include blocking probes, instructional materials describing how to use the kit contents in detecting 20q13 amplicons. The kits may also include one or more of the following: various labels or labeling agents to facilitate the detection of the probes, reagents for the hybridization including buffers, a metaphase spread, bovine serum albumin (BSA) and other blocking agents, sampling devices including fine needles, swabs, aspirators and the like, positive and negative hybridization controls and so forth.

Expression of cDNA clones

One may express the desired polypeptides encoded by the cDNA clones disclosed here, or by subsloning cDNA portions of genomic sequences in a recombinantly engineered cell such as bacteria, yeast, insect (especially employing baculoviral vectors), or mammalian cell. It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of the cDNAs. No attempt to describe in detail the various methods known for the expression of proteins in prokaryotes or eukaryotes will be made.

25 In brief summary, the expression of natural or synthetic nucleic acids encoding polypeptides of the invention will typically be achieved by operably linking the DNA or cDNA to a promoter (which is either constitutive or inducible), followed by incorporation into an expression vector. The vectors can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the DNA encoding the polypeptides. To obtain high level expression of a cloned gene, it is desirable to construct expression plasmids which

30

contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator.

Examples of regulatory regions suitable for this purpose in *E. coli* are the promoter and operator region of the *E. coli* tryptophan biosynthetic pathway as described by Yanofsky, C., 1984, J. Bacteriol., 158:1018-1024 and the leftward promoter of phage lambda (P_L) as described by Herskowitz, I. and Hagen, D., 1980, Ann. Rev. Genet., 14:399-445. The inclusion of selection markers in DNA vectors transformed in *E. coli* is also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, or chloramphenicol. Expression systems are available using *E. coli*, *Bacillus* sp. (Palva, I et al., 1983, Gene 22:229-235; Mosbach, K. et al. Nature, 302:543-545 and *Salmonella*. *E. coli* systems are preferred.

The polypeptides produced by prokaryote cells may not necessarily fold properly. During purification from *E. coli*, the expressed polypeptides may first be denatured and then renatured. This can be accomplished by solubilizing the bacterially produced proteins in a chaotropic agent such as guanidine HCl and reducing all the cysteine residues with a reducing agent such as beta-mercaptoethanol. The polypeptides are then renatured, either by slow dialysis or by gel filtration. U.S. Patent No. 4,511,503.

A variety of eukaryotic expression systems such as yeast, insect cell lines and mammalian cells, are known to those of skill in the art. As explained briefly below, the polypeptides may also be expressed in these eukaryotic systems.

Synthesis of heterologous proteins in yeast is well known and described. *Methods in Yeast Genetics*, Sherman, F., et al., Cold Spring Harbor Laboratory, (1982) is a well recognized work describing the various methods available to produce the polypeptides in yeast. A number of yeast expression plasmids like YEp6, YEp13, YEp4 can be used as vectors. A gene of interest can be fused to any of the promoters in various yeast vectors. The above-mentioned plasmids have been fully described in the literature (Botstein, et al., 1979, Gene, 8:17-24; Broach, et al., 1979, Gene, 8:121-133).

Illustrative of cell cultures useful for the production of the polypeptides are cells of insect or mammalian origin. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be used.

Illustrative examples of mammalian cell lines include VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, W138, BHK, Cos-7 or MDCK cell lines.

As indicated above, the vector, *e. g.*, a plasmid, which is used to transform the host cell, preferably contains DNA sequences to initiate transcription and sequences to control the translation of the antigen gene sequence. These sequences are referred to as expression control sequences. When the host cell is of insect or
5 mammalian origin illustrative expression control sequences are often obtained from the SV-40 promoter (Science, 222:524-527, 1983), the CMV I.E. Promoter (Proc. Natl. Acad. Sci. 81:659-663, 1984) or the metallothionein promoter (Nature 296:39-42, 1982). The cloning vector containing the expression control sequences is cleaved using restriction enzymes and adjusted in size as necessary or desirable and ligated with the
10 desired DNA by means well known in the art.

As with yeast, when higher animal host cells are employed, polyadenylation or transcription terminator sequences from known mammalian genes need to be incorporated into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate
15 splicing of the transcript may also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague, J. *et al.*, 1983, J. Virol. 45: 773-781).

Additionally, gene sequences to control replication in the host cell may be incorporated into the vector such as those found in bovine papilloma virus type-vectors. Saveria-Campo, M., 1985, "Bovine Papilloma virus DNA a Eukaryotic Cloning Vector"
20 in DNA Cloning Vol. II a Practical Approach Ed. D.M. Glover, IRL Press, Arlington, Virginia pp. 213-238.

Therapeutic and other uses of cDNAs and their gene products

The cDNA sequences and the polypeptide products of the invention can be used to modulate the activity of the gene products of the endogenous genes corresponding
25 to the cDNAs. By modulating activity of the gene products, pathological conditions associated with their expression or lack of expression can be treated. Any of a number of techniques well known to those of skill in the art can be used for this purpose.

The cDNAs of the invention are particularly used for the treatment of various cancers such as cancers of the breast, ovary, bladder, head and neck, and colon.
30 Other diseases may also be treated with the sequences of the invention. For instance, as noted above, GCAP (SEQ. ID. No. 6) encodes a guanino cyclase activating protein which is involved in the biosynthesis of cyclic AMP. Mutations in genes involved in the biosynthesis of cyclic AMP are known to be associated with hereditary retinal

degenerative diseases. These diseases are a group of inherited conditions in which progressive, bilateral degeneration of retinal structures leads to loss of retinal function. These diseases include age-related macular degeneration, a leading cause of visual impairment in the elderly; Leber's congenital amaurosis, which causes its victims to be born blind; and retinitis pigmentosa ("RP"), one of the most common forms of inherited blindness. RP is the name given to those inherited retinopathies which are characterized by loss of retinal photoreceptors (rods and cones), with retinal electrical responses to light flashes (i.e. eleetroretinograms, or "ERGs") that are reduced in amplitude.

The mechanism of retinal photoreceptor loss or cell death in different retinal degenerations is not fully understood. Mutations in a number of different genes have been identified as the primary genetic lesion in different forms of human RP. Affected genes include rhodopsin, the alpha and beta subunits of cGMP photodiesterase, and peripherin-RDS (Dryja, T. P. et al., *Invest. Ophthalmol. Vis. Sci.* 36, 1197-1200 (1995)). In all cases the manifestations of the disorder regardless of the specific primary genetic mutation is similar, resulting in photoreceptor cell degeneration and blindness.

Studies on animal models of retinal degeneration have been the focus of many laboratories during the last decade. The mechanisms that are altered in some of the mutations leading to blindness have been elucidated. This would include the inherited disorders of the *rd* mouse. The *rd* gene encodes the beta subunit of cGMP-phosphodiesterase (PDE) (Bowes, C. et al., *Nature* 347, 677-680 (1990)), an enzyme of fundamental importance in normal visual function because it is a key component in the cascade of events that takes place in phototransduction.

The polypeptides encoded by the cDNAs of the invention can be used as immunogens to raise antibodies either polyclonal or monoclonal. The antibodies can be used to detect the polypeptides for diagnostic purposes, as therapeutic agents to inhibit the polypeptides, or as targeting moieties in immunotoxins. The production of monoclonal antibodies against a desired antigen is well known to those of skill in the art and is not reviewed in detail here.

Those skilled in the art recognize that there are many methods for production and manipulation of various immunoglobulin molecules. As used herein, the terms "immunoglobulin" and "antibody" refer to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. Immunoglobulins may

exist in a variety of forms besides antibodies, including for example, Fv, Fab, and F(ab)₂, as well as in single chains. To raise monoclonal antibodies, antibody-producing cells obtained from immunized animals (*e.g.*, mice) are immortalized and screened, or screened first for the production of the desired antibody and then immortalized. For a discussion of general procedures of monoclonal antibody production see Harlow and Lane, *Antibodies, A Laboratory Manual* Cold Spring Harbor Publications, N.Y. (1988).

The antibodies raised by these techniques can be used in immunodiagnostic assays to detect or quantify the expression of gene products from the nucleic acids disclosed here. For instance, labeled monoclonal antibodies to polypeptides of the invention can be used to detect expression levels in a biological sample. For a review of the general procedures in diagnostic immunoassays, see *Basic and Clinical Immunology* 7th Edition D. Stites and A. Terr ed. (1991).

The polynucleotides of the invention are particularly useful for gene therapy techniques well known to those skilled in the art. Gene therapy as used herein refers to the multitude of techniques by which gene expression may be altered in cells. Such methods include, for instance, introduction of DNA encoding ribozymes or antisense nucleic acids to inhibit expression as well as introduction of functional wild-type genes to replace mutant genes (*e.g.*, using wild-type GCAP genes to treat retinal degeneration). A number of suitable viral vectors are known. Such vectors include retroviral vectors (see Miller, *Curr. Top. Microbiol. Immunol.* 158: 1-24 (1992); Salmons and Gunzburg, *Human Gene Therapy* 4: 129-141 (1993); Miller et al., *Methods in Enzymology* 217: 581-599, (1994)) and adeno-associated vectors (reviewed in Carter, *Curr. Opinion Biotech.* 3: 533-539 (1992); Muzyczka, *Curr. Top. Microbiol. Immunol.* 158: 97-129 (1992)). Other viral vectors that may be used within the methods include adenoviral vectors, herpes viral vectors and Sindbis viral vectors, as generally described in, *e.g.*, Jolly, *Cancer Gene Therapy* 1:51-64 (1994); Latchman, *Molec. Biotechnol.* 2:179-195 (1994); and Johanning et al., *Nucl. Acids Res.* 23:1495-1501 (1995).

Delivery of nucleic acids linked to a heterologous promoter-enhancer element via liposomes is also known (*see, e.g.*, Brigham, *et al.* (1989) *Am. J. Med. Sci.*, 298:278-281; Nabel, *et al.* (1990) *Science*, 249:1285-1288; Hazinski, *et al.* (1991) *Am. J. Resp. Cell Molec. Biol.*, 4:206-209; and Wang and Huang (1987) *Proc. Natl. Acad. Sci. (USA)*, 84:7851-7855); coupled to ligand-specific, cation-based transport systems (Wu and Wu (1988) *J. Biol. Chem.*, 263:14621-14624). Naked DNA expression

vectors have also been described (Nabel *et al.* (1990), *supra*); Wolff *et al.* (1990) *Science*, 247:1465-1468).

The nucleic acids and encoded polypeptides of the invention can be used directly to inhibit the endogenous genes or their gene products. For instance, 5 Inhibitory nucleic acids may be used to specifically bind to a complementary nucleic acid sequence. By binding to the appropriate target sequence, an RNA-RNA, a DNA-DNA, or RNA-DNA duplex is formed. These nucleic acids are often termed "antisense" because they are usually complementary to the sense or coding strand of the gene, although approaches for use of "sense" nucleic acids have also been developed. The 10 term "inhibitory nucleic acids" as used herein, refers to both "sense" and "antisense" nucleic acids. Inhibitory nucleic acid methods encompass a number of different approaches to altering expression of specific genes that operate by different mechanisms.

In brief, inhibitory nucleic acid therapy approaches can be classified into those that target DNA sequences, those that target RNA sequences (including pre-mRNA and mRNA), those that target proteins (sense strand approaches), and those that cause 15 cleavage or chemical modification of the target nucleic acids (ribozymes). These different types of inhibitory nucleic acid technology are described, for instance, in Helene, C. and Toulme, J. (1990) *Biochim. Biophys. Acta.*, 1049:99-125. Inhibitory nucleic acid complementary to regions of c-myc mRNA has been shown to inhibit c-myc 20 protein expression in a human promyelocytic leukemia cell line, HL60, which overexpresses the c-myc protooncogene. See Wickstrom E.L., *et al.*, (1988) *PNAS (USA)*, 85:1028-1032 and Harel-Bellan, A., *et al.*, (1988) *Exp. Med.*, 168:2309-2318.

The encoded polypeptides of the invention can also be used to design molecules (peptidic or nonpeptidic) that inhibit the endogenous proteins by, for instance, 25 inhibiting interaction between the protein and a second molecule specifically recognized by the protein. Methods for designing such molecules are well known to those skilled in the art.

For instance, polypeptides can be designed which have sequence identity with the encoded proteins or may comprise modifications (conservative or non- 30 conservative) of the sequences. The modifications can be selected, for example, to alter their *in vivo* stability. For instance, inclusion of one or more D-amino acids in the peptide typically increases stability, particularly if the D-amino acid residues are substituted at one or both termini of the peptide sequence.

The polypeptides can also be modified by linkage to other molecules. For example, different N- or C-terminal groups may be introduced to alter the molecule's physical and/or chemical properties. Such alterations may be utilized to affect, for example, adhesion, stability, bio-availability, localization or detection of the molecules.

5 For diagnostic purposes, a wide variety of labels may be linked to the terminus, which may provide, directly or indirectly, a detectable signal. Thus, the polypeptides may be modified in a variety of ways for a variety of end purposes while still retaining biological activity.

EXAMPLES

10 The following examples are offered to illustrate, but not to limit the present invention.

Example 1

PROGNOSTIC IMPLICATIONS OF AMPLIFICATION OF CHROMOSOMAL REGION 20q13 IN BREAST CANCER

15 **Patients and tumor material.**

Tumor samples were obtained from 152 women who underwent surgery for breast cancer between 1987 and 1992 at the Tampere University or City Hospitals. One hundred and forty-two samples were from primary breast carcinomas and 11 from metastatic tumors. Specimens from both the primary tumor and a local metastasis were available from one patient. Ten of the primary tumors that were either *in situ* or mucinous carcinomas were excluded from the material, since the specimens were considered inadequate for FISH studies. Of the remaining 132 primary tumors, 128 were invasion ductal and 4 lobular carcinomas. The age of the patients ranged from 29 to 92 years (mean 61). Clinical follow-up was available from 129 patients. Median follow-up period was 45 months (range 1.4-1.77 months). Radiation therapy was given to 77 of the 129 patients (51 patients with positive and 26 with negative lymph nodes), and systemic adjuvant therapy to 36 patients (33 with endocrine and 3 with cytotoxic chemotherapy). Primary tumor size and axillary node involvement were determined according to the tumor-node metastasis (TNM) classification. The histopathological diagnosis was evaluated according to the World Health Organization (11). The carcinomas were graded on the basis of the tubular arrangement of cancer cells, nuclear atypia, and frequency of mitotic or hyperchromatic nuclear figures according to Bloom and Richardson, *Br. J. Cancer*, 11: 359-377 (1957).

Surgical biopsy specimens were frozen at -70°C within 15 minutes of removal. Cryostat sections (5-6 μm) were prepared for intraoperative histopathological diagnosis, and additional thin sections were cut for immunohistochemical studies. One adjacent 200 μm thick section was cut for DNA flow cytometric and FISH studies.

5 **Cell preparation for FISH.**

After histological verification that the biopsy specimens contained a high proportion of tumor cells, nuclei were isolated from 200 μm frozen sections according to a modified Vindelov procedure for DNA flow cytometry, fixed and dropped on slides for FISH analysis as described by Hytytinen *et al.*, *Cytometry* 16: 93-99 (1994). Foreskin fibroblasts were used as negative controls in amplification studies and were prepared by harvesting cells at confluence to obtain G1 phase enriched interphase nuclei. All samples were fixed in methanol-acetic-acid (3:1).

10 **Probes.**

15 Five probes mapping to the 20q13 region were used (*see* Stokke, *et al.*, *Genomics*, 26: 134-137 (1995)). The probes included P1-clones for melanocortin-3-receptor (probe MC3R, fractional length from p-arm telomere (Flpter 0.81) and phosphoenolpyruvate carboxy kinase (PCK, Flpter 0.84), as well as anonymous cosmid clones RMC20C026 (Flpter 0.79). In addition, RMC20C001 (Flpter 0.825) and RMC20C030 (Flpter 0.85) were used. Probe RMC20C001 was previously shown to define the region of maximum amplification (Tanner *et al.*, *Cancer Res*, 54: 4257-4260 (1994)). One cosmid probe mapping to the proximal p-arm, RMC20C038 (FLpter 0.237) was used as a chromosome-specific reference probe. Test probes were labeled with biotin-14-dATP and the reference probe with digoxigenin-11-dUTP using nick translation (Kallioniemi *et al.*, *Proc. Natl Acad Sci USA*, 89: 5321-5325 (1992)).

20 **Fluorescence in situ hybridization.**

25 Two-color FISH was performed using biotin-labeled 20q13-specific probes and digoxigenin-labelled 20p reference probe essentially as described (*Id.*). Tumor samples were postfixed in 4% paraformaldehyde/phosphate-buffered saline for 5 min at 4°C prior to hybridization, dehydrated in 70%, 85% and 100% ethanol, air dried, and incubated for 30 min at 80°C. Slides were denatured in a 70% formamide/2x standard saline citrate solution at 72-74°C for 3 min, followed by a proteinase K digestion (0.5 $\mu\text{g}/\text{ml}$). The hybridization mixture contained 18 ng of each of the labeled probes and 10 μg human placental DNA. After hybridization, the probes were detected

immunochemically with avidin-FITC and anti-digoxigenin Rhodamine. Slides were counterstained with 0.2 μ M 4,6-diamidino-2-phenylindole (DAPI) in an antifade solution.

Fluorescence microscopy and scoring of signals in interphase nuclei.

A Nikon fluorescence microscope equipped with double band-pass filters (Chromatechnology, Brattleboro, Vermont, USA) and 63 x objective (NA 1.3) was used for simultaneous visualization of FITC and Rhodamine signals. At least 50 non-overlapping nuclei with intact morphology based on the DAPI counterstaining were scored to determine the number of test and reference probe hybridization signals. Leukocytes infiltrating the tumor were excluded from analysis. Control hybridizations to normal fibroblast interphase nuclei were done to ascertain that the probes recognized a single copy target and that the hybridization efficiencies of the test and reference probes were similar.

The scoring results were expressed both as the mean number of hybridization signals per cell and as mean level of amplification (= mean of number of signals relative to the number of reference probe signals).

DNA flow cytometry and steroid receptor analyses.

DNA flow cytometry was performed from frozen 200 μ m sections as described by Kallioniemi, *Cytometry* 9: 164-169 (1988). Analysis was carried out using an EPICS C flow cytometer (Coulter Electronics Inc., Hialeah, Florida, USA) and the MultiCycle program (Phoenix Flow Systems, San Diego, California, USA). DNA-index over 1.07 (in over 20% of cells) was used as a criterion for DNA aneuploidy. In DNA aneuploid histograms, the S-phase was analyzed only from the aneuploid clone. Cell cycle evaluation was successful in 86% (108/126) of the tumors.

Estrogen (ER) and progesterone (PR) receptors were detected immunohistochemically from cryostat sections as previously described (17). The staining results were semiquantitatively evaluated and a histoscore greater than or equal to 100 was considered positive for both ER and PR (17).

Statistical Methods.

Contingency tables were analyzed with Chi square test for trend. Association between S-phase fraction (continuous variable) and 20q13 amplification was analyzed with Kruskal-Wallis test. Analysis of disease-free survival was performed using the BMDPIL program and Mautel-Cox test and Cox's proportional hazards model (BMDP2L program) was used in multivariate regression analysis (Dixon *BMDP*

Statistical Software. London, Berkeley, Los Angeles: University of California Press, (1981)).

Amplification of 20q13 in primary breast carcinomas by fluorescence *in situ* hybridization.

5 The minimal region probe RMC20C001 was used in FISH analysis to assess the 20q13 amplification. FISH was used to analyze both the total number of signals in individual tumor cells and to determine the mean level of amplification (mean copy number with the RMC20C001 probe relative to a 20p-reference probe). In addition, the distribution of the number of signals in the tumor nuclei was also assessed.

10 Tumors were classified into three categories: no, low and high level of amplification. Tumors classified as not amplified showed less than 1.5 than 1.5 fold-copy number of the RMC20C001 as compared to the p-arm control. Those classified as having low-level amplification had 1.5-3-fold average level of amplification. Tumors showing over 3-fold average level of amplification were classified as highly amplified.

15 The highly amplified tumors often showed extensive intratumor heterogeneity with up to 40 signals in individual tumor cells. In highly amplified tumors, the RMC20C001 probe signals were always arranged in clusters by FISH, which indicates location of the amplified DNA sequences in close proximity to one another *e.g.* in a tandem array. Low level 20q13 amplification was found in 29 of the 132 primary tumors (22%), whereas nine cases (6.8%) showed high level amplification. The overall prevalence of increased copy number in 20q13 was thus 29% (38/132).

Defining the minimal region of amplification.

20 The average copy number of four probes flanking RMC20C001 was determined in the nine highly amplified tumors. The flanking probes tested were melanocortin-3-receptor (MC3R, FLpter 0.81), phosphoenolpyruvate carboxykinase (PCK, 0.84), RMC20C026 (0.79) and RMC20C030 (0.85). The amplicon size and location varied slightly from one tumor to another but RMC20C001 was the only probe consistently highly amplified in all nine cases.

Association of 20q13 amplification with pathological and biological features.

25 The 20q13 amplification was significantly associated with high histologic grade of the tumors ($p=0.01$). This correlation was seen both in moderately and highly amplified tumors (Table 4). Amplification of 20q13 was also significantly associated with aneuploidy as determined by DNA flow cytometry ($p=0.01$, Table 4) The mean

cell proliferation activity, measured as the percentage of cells in the S-phase fraction, increased ($p=0.0085$ by Kruskal-Wallis test) with the level of amplification in tumors with no, low and high levels of amplification (Table 4). No association was found with the age of the patient, primary tumor size, axillary nodal or steroid hormone-receptor status (Table 4).

5

Table 4. Clinicopathological correlations of amplification at chromosomal region 20q13 in 132 primary breast cancers.

	Pathobiologic feature	20q13 amplification status			p-value ¹
		NO Number of patients (%)	LOW LEVEL Number of patients (%)	HIGH LEVEL Number of patients (%)	
10	All primary tumors	94 (71%)	29 (22%)	9 (6.8%)	
15	Age of patients				
	< 50 years	17 (65%)	6 (23%)	3 (12%)	.39
20	≥ 50 years	77 (73%)	23 (22%)	6 (5.7%)	
	Tumor size				
25	< 2 cm	33 (79%)	7 (17%)	2 (4.8%)	
	≥ 2 cm	58 (67%)	22 (25%)	7 (8.0%)	.16
30	Nodal status				
	Negative	49 (67%)	19 (26%)	5 (6.8%)	
35	Positive	41 (75%)	10 (18%)	4 (7.3%)	.41
	Histologic grade				
40	I - II	72 (76%)	18 (19%)	5 (5.3%)	
	III	16 (52%)	11 (35%)	4 (13%)	.01
45	Estrogen receptor status				
50	Negative	30 (67%)	10 (22%)	5 (11%)	
	Positive	59 (72%)	19 (23%)	4 (4.9%)	.42
55	Progesterone receptor status				
	Negative	57 (69%)	20 (24%)	6 (7.2%)	
60	Positive	32 (74%)	8 (19%)	3 (7.0%)	.53
	DNA ploidy				
65	Diploid	45 (82%)	8 (14.5%)	2 (3.6%)	
	Aneuploid	44 (62%)	20 (28%)	7 (10%)	.01
70	S-phase fraction (%)	mean ± SD 9.9 ± 7.2	mean ± SD 12.6 ± 6.7	mean ± SD 19.0 ± 10.5	.0085 ¹

¹ Kruskal-Wallis Test.

Relationship between 20q13 amplification and disease-free survival.

40

Disease-free survival of patients with high-level 20q13 amplification was significantly shorter than for patients with no or only low-level amplification ($p=0.04$). Disease-free survival of patients with moderately amplified tumors did not differ significantly from that of patients with no amplification. Among the node-negative

patients (n=79), high level 20q13 amplification was a highly significant prognostic factor for shorter disease-free survival ($p=0.002$), even in multivariate Cox's regression analysis ($p=0.026$) after adjustment for tumor size ER, PR grade, ploidy and S-phase fraction.

5 **20q13 amplification in metastatic breast tumors.**

Two of 11 metastatic breast tumors had low level and one high level 20q13 amplification. Thus, the overall prevalence (27%) of increased 20q13 copy number in metastatic tumors was a similar to that observed in the primary tumors. Both a primary and a metastatic tumor specimens were available from one of the patients.

10 This 29-year old patient developed a pectoral muscle infiltrating metastasis eight months after total mastectomy. The patient did not receive adjuvant or radiation therapy after mastectomy. The majority of tumor cells in the primary tumor showed a low level amplification, although individual tumor cells (less than 5% of total) contained 8-20 copies per cell by FISH. In contrast, all tumor cells from metastasis showed high level 15 20q13 amplification (12-50 copies per cell). The absolute copy number of the reference probe remained the same suggesting that high level amplification was not a result of an increased degree of aneuploidy.

Diagnostic and Prognostic Value of the 20q13 Amplification.

20 The present findings suggest that the newly-discovered 20q13 amplification may be an important component of the genetic progression pathway of certain breast carcinomas. Specifically, the foregoing experiments establish that: 1) High-level 20q13 amplification, detected in 7% of the tumors, was significantly associated with decreased disease-free survival in node-negative breast cancer patients, as well as with indirect indicators of high-malignant potential, such as high grade and S-phase fraction. 2) 25 Low-level amplification, which was much more common, was also associated with clinicopathological features of aggressive tumors, but was not prognostically significant. 3) The level of amplification of RMC20C001 remains higher than amplification of nearby candidate genes and loci indicating that a novel oncogene is located in the vicinity of RMC20C001.

30 High-level 20q13 amplification was defined by the presence of more than 3-fold higher copy number of the 20q13 amplification is somewhat lower than the amplification frequencies reported for some of the other breast cancer oncogenes, such as ERBB2 (17q12) and Cyclin-D (11q13) (Borg *et al.*, *Oncogene*, 6: 137-143 (1991), Van

de Vijver *et al.* *Adv. Canc. Res.*, 61: 25-56 (1993)). However, similar to what has been previously found with these other oncogenes (Swab, *et al.*, *Genes Chrom. Canc.*, 1: 181-193 (1990), Borg *et al.*, *supra*.), high-level 20q13 amplification was more common in tumors with high grade or high S-phase fraction and in cases with poor prognosis.

5 Although only a small number of node-negative patients was analyzed, our results suggest that 20q13 amplification might have independent role as a prognostic indicator. Studies to address this question in large patient materials are warranted. Moreover, based on these survival correlations, the currently unknown, putative oncogene amplified in this locus may confer an aggressive phenotype. Thus, cloning of this gene is an
10 important goal. Based on the association of amplification with highly proliferative tumors one could hypothesize a role for this gene in the growth regulation of the cell.

The role of the low-level 20q13 amplification as a significant event in tumor progression appears less clear. Low-level amplification was defined as 1.5-3-fold increased average copy number of the 20q13 probe relative to the p-arm control. In
15 addition, these tumors characteristically lacked individual tumor cells with very high copy numbers, and showed a scattered, not clustered, appearance of the signals. Accurate distinction between high and low level 20q13 amplification can only be reliably done by FISH, whereas Southern and slot blot analyses are likely to be able to detect only high-level amplification, in which substantial elevation of the average gene copy
20 number takes place. This distinction is important, because only the high amplified tumors were associated with adverse clinical outcome. Tumors with low-level 20q13 amplification appeared to have many clinicopathological features that were in between of those found for tumors with no and those with high level amplification. For example, the average tumor S-phase fraction was lowest in the non-amplified tumors and highest in
25 the highly amplified tumors. One possibility is that low-level amplification precedes the development of high level amplification. This has been shown to be the case, *e.g.*, in the development of drug resistance-gene amplification *in vitro* (Stark, *Adv. Canc. Res.*, 61: 87-113 (1993)). Evidence supporting this hypothesis was found in one of our patients, whose local metastasis contained a much higher level of 20q13 amplification
30 than the primary tumor operated 8 months earlier.

Finally, our previous paper reported a 1.5 Mb critical region defined by RMC20C001 probe and exclusion of candidate genes in breast cancer cell lines and in a limited number of primary breast tumors. Results of the present study confirm these

findings by showing conclusively in a larger set of primary tumors that the critical region of amplification is indeed defined by this probe.

The present data thus suggest that the high-level 20q13 amplification may be a significant step in the progression of certain breast tumors to a more malignant phenotype. The clinical and prognostic implications of 20q13 amplification are striking and location of the minimal region of amplification at 20q13 has now been defined.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.

Discussion of the Accompanying Sequence Listing

SEQ ID NOs:1-10 and 12-13 provide nucleic acid sequences. In each case, the information is presented as a DNA sequence. One of skill will readily understand that the sequence also describes the corresponding RNA (*i.e.*, by substitution of the T residues with U residues) and a variety of conservatively modified variations thereof. The complementary sequence is fully described by comparison to the existing sequence, *i.e.*, the complementary sequence is obtained by using standard base pairing rules for DNA (*e.g.*, A to T, C to G). In addition, the nucleic acid sequence provides the corresponding amino acid sequence by translating the given DNA sequence using the genetic code.

For SEQ ID NO 11, the information is presented as a polypeptide sequence. One of skill will readily understand that the sequence also describes all of the corresponding RNA and DNA sequences which encode the polypeptide, by conversion of the amino acid sequence into the corresponding nucleotide sequence using the genetic code, by alternately assigning each possible codon in each possible codon position. Similarly, each nucleic acid sequence which is provided also inherently provides all of the nucleic acids which encode the same protein, since one of skill simply translates a selected nucleic acid into a protein and then uses the genetic code to reverse translate all possible nucleic acids from the amino acid sequence.

The sequences also provide a variety of conservatively modified variations by substituting appropriate residues with the exemplar conservative amino acid substitutions provided, *e.g.*, in the Definitions section above.

SEQUENCE LISTING

SEQ. ID. No. 1

3bf4 3000 bp

CCGCCCCGGGGCGCTGGCTGCACTCAGGCCGGAGCCGGAGCTAGCGGCCGCCATGTCCCACCAAGAC
 5 CGGCATCCAAGCAAGTGAAGATGTTAAAGAGATCTTGCCAGGCCAGAAATGGAAGTACAGACTTCTGAAAAA
 TATCTATTGAAAATGAGCAACTTGTGATTGGATCATATAGTCAGCCTCAGATTCTGGGATAAGGATTATGAT
 TCCTTTGTTAACCCCTGTTGGAGGACAAACAACCAGTCATATATTATTAGCTAGGTTAGATTCTCAGAATGCCA
 GGGATATGAATGGATATTCAATTGCATGGTCTCCAGATCATTCTCATGTCGTCAGAAATGGTATGCAGCAA
 10 CAAGAGCAACTCTGAAGAAGGAATTGGAGGTGGCACATTAAAGATGAAGTATTGGAACAGTAAGGAAGAT
 GTATCATTACATGGATATAAAAATACTTGCTGTCACAATCTTCCCTGCCCCACTGACTGCAGCTGAGGAAGA
 ACTACGACAGATTAAGCAATGAGGTACAGACTGACGCTGGGTGTGGACACTAACAGCTCAACAACTACAAGGAG
 TAGCATTCCCATTCTCGAGAAGCCTTCAGGCTTGGAAAAATTGAATAATAGACAGCTCAACTATGTCAG
 TTGGAATAGATATAAAAATGAAATTATAATTGGCAACACAACAAATACAGAACTGAAAGATTGCCAAA
 15 GAGGATCCCAAGGATTCACTGCTTACCATTTCTGTATAAACATTCCATGAAGGAGACTATTAGAGT
 CCATAGTTTATTTATTCAATGCCTGGATACACATGCAGTATAAGAGAGCGGATGCTGTATTCTAGCTGCAAG
 AGCCGCTGCTAGAAATTGTAGAAAGACAACACTACAATGGATGTAATTAGAAAGATCGAGATAGACAATGGGA
 TGAGTGACTGCAGACTCCATTATGAAGAAGTACATCCAAAGCAGCATGCACACAAGCAAAGTTTGCAAAAC
 CAAAAGGTCTGCAGGAAAAGAGGAATTGAAGACTAATTAGGGCCAGCGGAAACTGAAGCTACTACTGAT
 20 TAAAGTCATCACATTAAACATTGTAATACTAGTTTTAAAGTCCAGCTTGTACAGGAGAACTGAAATCA
 TTCCATGTTGATATAAGTAGGAAAAAAATTGTAATTGACTTTTGAAATAGCACTTCTGTGTGTTTT
 AAAATTAAATGTTAGAAGACTCATGATTCTATTGAGTTAAAGCTAGAAAGGGTTCAACATAATGTTA
 ATTTGTCACACTGTTCATAGCGTGTGATTCCACACTTCATGTTAAATTATACAGTTGGCCAG
 TTCTAGAAAGTCATGTCCTAAAGGGTAAACTACTACTTTCTGTGGGACAGAAAGACCTTAAATATTCA
 25 ATTACTTAATGAAATATGTAAGGACAGGCTAGAGTATTCTAAGCTGGAAACTAGTGTGCTTGGAAAAGC
 CGCAAGTTGCTTACTCCGAGTAGCTGCTAGCTGTCAGACTGCTGAGATCATGTCAGCTCACTCT
 GTGCTTATATTGCACTGAGCTTTATATTGACTTTTTAATAGCATTAAATTGAGATCAGCTCACTCT
 GAAACTTAAAGGGTACCAAGATATTCTATGCAAGGATTCTGATGACATTAAAGACTTAAACAGCCTTAA
 GTAAATTATCTTCTAATGCTCTGTGAGGCCAACATTATGAAATTAAATTATCATTCA
 AAGGAAACAAAAATGTTGAGTTAAAATCAGGATTGACTTTCTCCAAAACCACATTTATGGCAAA
 30 TTGTGTTCTTATCACTTCAGCAGCAAAACTCAGATTAAACTTAAACTCTGTTCTAATGCTTGC
 CGTAGATAAAACCTTAATCTAGTAAACTGTTGATTTCTGAAACTTAAACACATTAACTGTTCTAATGCTTGC
 ATTATCAGTTAACACCTAGAGAGATTGAGCCATATTCTTGTGATTTGAAATAGAGGGAGCTAGAACAC
 TTAATGTTAATCTGTTAACCTGCTGCAAGAGCCATAACTTGAGGCAATTCTAAATGAACTGTGGGATCC
 AGGATTGTAATTCTGATCTAAACATTATGCTGCATAATCACTTACGAAATGCACTTCAAGTGTGA
 35 AGCACTCATTCTAAACCTTATTATCAAGGTAATATGACACCTTCAGAAATTGTTGAGTAAGTAAAG
 CATATTGAAATAATTGGGGTTGACAGATTAAATGAAATTAGTATTGTTGTTGTTGTTGTTACAA
 ATAATCAGACTATAATATTAAACATGCCAAATAACTGACAAATAATGTCACTTGTGTTACTAAAGAGATAAAGT
 TGTTCCATGGGTGTACACGTAGACAGACACACATACACCCAAATTATGCAATAAGAATCTGGAGCAGACCAT
 AGCTGAAGCTGTTATTCTGCTCAGGAAGACTACCTGTCAGGTTAAATATTAGAAGTGAATGTT
 40 TCTGTAACCATCTATGTCATAATTACTCTAAATTCTCAACTACACTACATTAAAGTAATGGACATTCCAGAAAT
 AGATGTGATTATGTTAAACTAATTATTAAACCAATGATTGCTGAAATCAGTGTGACATTGTTGTTATAG
 AGTATAACTCATGTTACAGTATGTTAGTGGCAGTACATACCTAGATGGTAATAACATATTCCAGTA
 AATTATATAGCAGTGAAGAATTACATGCCTCTGGGACATTGAAATTGTCATTATCACAATAAAA
 TTTTTCTCTTAAAAAAACAAAGAAAAAA

45

SEQ. ID. No. 2

1b11 723 bp

TGGAAGCTGTCATGGTTACCGTCTCTAACGTTGGACTCTTAAAGAAAATGATTATTCTGGTTCTAGACAGGCC
 50 AAATGTAATTACCTACGTGGCAGATAAAAGAGGTGGCTACTAGATTGATTGGTATTGAGCATGCTCTGA
 ATGACAGTCCCCAAAAGGGACTCTTATCCGTTCTCCCTGGGAAGGGCTTTGCCACTTCCATGTCATG
 TGGCAGTTGAGCTGGAAATTGGTGTGTTACACATAAGCATTACTCTCAAGATGTCCTGTGAGAAAT
 GGTCTAGATTCAAAACTGTAGCTACTATGTCAGGGGGCAGCAAGGACCCACTTGTAAACATGTTT
 GGGGAATGTTGTTCTATTACCTGGCAAATAATCAGGTGGTGTGAGTCACCAGTAGAG
 ATTATAAGTCCAAGGAAGTGAATCAGCCTTACAAACAGTGGACCTCAACGAAGGAGATGCTGCACCTGAACC
 55 CACWGAAGCGAAACTCAAAGAGAAGAAAGCAACCAAGAACCTCTGATGRGCTTCTCAGACAAATGGTAA
 GCCCTTACTCCAGTATAGGAAACCTAACGATACCTAGAGGGCTTTGGGAACAATGGGCTCATGCCACAGGT
 AGTAGGAGACATAATTGTAAGCTGGTGTGATGGAATGTGAATGGAATATGGATTGCG

60

SEQ. ID. No. 3

cc49 1507 bp

GCAGGTTGCTGGGATTGACTTCTGCTCAATTGAAACACTCATTCAATGGAGACAAAGAGCACTAATGCTTGT
 GCTGATTCAATTGAAATCGAGGCATTGGAACCCCTGTATGCCCTGTTGTGAGAAGAACAGTGACACCATCA
 CTGAGCTTCTAAAGTTCAGAAGAAGTTAGAGGACTACACTTTCTTGTGAACTTTATAATAATATTGCT
 CTGGTTTGGAACCCAGGACTGTTAGAGGGTGAAGTGCACAGGTCTACAGTGGCCTTAATCCAACCTCAGAAATT

USPTO 2013022730

GCCCAACGGAACCTTGAGATTATGCAATCGAAAGTGACAGGAAACATGCCAActCAATCCCTTTAATGTAC
 ATGGATGGCCAAGAGTATTGGCAGCTCTTCGAGTCCGATGGAGATGGAGATGCCCTGTCATGAAAGGGC
 CCNCTGTTGTCATTCCGAGCTACACAAGAAAAAATGTCATCCGAATCGAGGGAAATATGCCCTGGATTG
 5 CATGTTCTGCAGCCAGACCTCACACATTCAAGAACCTTAATAAACATGTCATGCAACACCAGGCTACCC
 TCTGTGAACCAGCAGTCTCGGGTTGAAGCAGAGTATCTCAGTCCGCTGATAAAAGTCAAGTGCAGAAGA
 CCTCCCAAGGAAAAGAATGCAAGGAAATGAATGTCAGTGTAGGGTACAGATGTCAGAAGAAGATTCA
 TGATGTTGAGATCCACATGAGAACACACAAAGATCTTCACCTACGGGTGATAATGTCAGAAGAAGATTCA
 AGGAGCCTGGTTCTTAAACATGCGGACRCAATAATGCAACATGGCAATCGGGGCCAGAAGCAAATGCA
 10 GGCTGGAGACTAGTCCAGCAACGATCAACGAGGTGTCAGGTGACCGCCGAGAGCATCTCCTCTTG
 CAAAATCTGCATGGTTGTCCTTCAATTCCAAATAAAGAAAGTCTAATTGAGCACCGCAAGGTGCACACCA
 AAAAAACTGCTTCGGTACCCAGCAGCGCAGACAGACTCTCCACAAGGAGGAATGCCGCTCGAGGGAGGAC
 TTCTGCAGTGTCAACTTGAGACAAAATCTCACCCCTGAAACCGGGAAAGAAGCCTGTCAGATGCATCCCT
 GCTCGATCCGTTACCCACCTTCCAGGCTTGGCAKTCGCTACCAAAGGAAWAGTTGCCATTGCAAGAAGTGA
 15 AGGAATTGGGCAAGAAGGGAGCACCGACAACGACGAGTCGAGTCCGAGAAGGAGCTGGAGAAACAAATAAG
 AACCAATTGTGCAAGGCTCTCGCAAGAGAAAGAGAAGTGCACAAACACTCCACGGCAAGGCCCTCGTGACGC
 GGATCCAAGTTACCCAGTAGCAAGGAGAACCCACTCACTGCTCCAGTGCAGGCTTCAGAACCTACC
 ACCAGCTGGTCTGCACTCCAGGGTCC

SEQ. ID. No. 4

20 cc43 2605 bp
 CAAGCTCGAAATAACCCCTCACTAAAGGGAAACAAAGCTGGAGCTCCACCGCGTGGCGGCCGCTCTAGAACTA
 GTGGATCCCCGGGCTGCAGGAATTGGCACGAGCTGGCTACTACGATGGGATGAGTTCGAGTGGCCGTGG
 CAGTATCGCTTCCCACCCCTCTTACGTTACAACCGAATGTCAGGACTCGGCAGAACAGCTGGCCGTGG
 25 CTCGCTGGTCTGCTTCTGCCGCTTGCAACAAACAGTCCAGCATGACGGTGTGATGAAAGCTCAGGAGAGCCGC
 TCTTCACAAACGTCAGCTAACAGCAGGCTCTGTGGAGTCGATCCAGATTGATTAGAGGAACGTAGGAAAG
 AAAGGGAAACCTCGAGTGGTTGATAAGAGCAAGTCCAGCTCTGATCATGTCAGGAGGCCAGAACAGGG
 GAAACTCATCTATCAGTGGTTCCAGGAGTGGCCAGAACACTCGTCTTACCTGTATGAACTGACTAATG
 GGGAAAGACACAGAGGATGAGGAGTCCACGGGCTGGATGAAGCCACTCTACTGCGGCTCTGCAGGCCCTACAG
 30 CAGGAGCACAAGGCCAGATCATCACTGTCAGCGATGGCCAGGGCTCAAGTTCTCTAGCAGGGACCTGTCTC
 CCTTACTTCTTACCTCCCACCTTCAGGGCTTCAAAAGGAGACAGACCCAGTGTCCCCAAAGACTGGATC
 TGTGACTCCACCAGACTCAAAGGACTCCAGTCTGAAGGCTGGGACCTGGGATGGGTTCTCACACCCCTA
 TGTCGTCCTGGATAGGGTGGAGGCTGAAGCACCCAGGGAGAAAATATGTCCTTCTGCTTCACACATGTAAGTACATA
 CCCATCCTAGACTGCTTCTGGAGCCAGGGTCTGTAACACTGACCTTATGTCGTTACACATGTAAGTACATA
 35 CACACATGCGCTGCAAGCACATGCTTCTGCTCTCTCCACCCCTTTAGCTGCTGGCTGCAGGCAGCTTCCAGGAATATGAAAGAT
 AGGCTGGTGGCTGGATCCCTCTAGGGATGGGGAGACCCCTGGCTGCAGGCAATATGAAAGAT
 AGGAGGCCACGGGCTGGCACTGAGAGGTGTGCCCCCACACCGATTATGATATAAAATCTCAACTCCAAA
 AAAAAAAAAAAACTGAGACTAGTTCTCTCTGAGAACACTAGTCTCGAGTTTTTTTTTTTTTT
 TTTTTTTTTTTTTTTGGCTTAAGGATTATTATTGTTCTCTTACAGTGTCCACTTTCTCTAC
 40 TTAATACTACTTCCAGTCAGAACAGGAAACCTTCTGAAAAAAAGTGTGACTGAAACTCCAAACCAACATGCCATA
 GTACACACTTTGAAAACAGATTGGAAAACCTTCTGAAAAAAAGTGTGACTGAAACTCCAAACCAACATGCCATA
 TTGTGATGTTGCTCATGAAAATGTTAAAAACCTGTTCTAGATAAGAACAGCTCAAGTTTTGTACAGCCT
 ACACATAGTACAAGGGCTCCCTATGATGATTCTCTGAGGACGAAATAATGTAATTGTTCAAGTTCTGGTTT
 ATAATCCTCGATCTCAGAGTGTGACTTAAACACCTACTCATGCAACAGAGAATAAGCACTCATATT
 TATAAATTATGACCAAAACTATTGAAATCTTATGAGACACAATATGCTGGACTAAAGCAATAA
 45 TTATTATTCTCAATGTCGTCTAACCTCAATGACTTGAATGCTTGTATATTGCTCTATGCTCA
 CCACACTGGCTTCTTCTGCTGAACAAGCC
 AACTGCTTCTGCCCTCAGGACCAGATATTGGACTCTCTTAAGAATTCTATTCTTAATTCTTTATCTGG
 50 GTAACCTAGTTTATCCAAACACTTCAGATCCTGCCGTAACAAACTCTCTTATAGAACGCCGTCATGACACTGTC
 TCTCTCTCCAAACATACTCACCAAGCACACATGTAAGACTAGATTAGAACCTCTGTTTCTTTCTACATCTT
 CTCTATCATGCTCCCTCATTATAATTCTTATTATGTCGTGAATGTCGCTCCAGTCAGTTCTCCTACT
 AAAACTATAAAACTCCGTAAGACCTGGGATCCTCCAAATTGTCATCACCCTAGTACAGTAGGAAACACAGTAAAGA
 TTCAATTGGTATTGTTGGAAATGAATGAATGTTGCTAGTAAAGTCTGGGGAAACCCAGGTGAGAAGAG
 55 CCTAGAAAGCAGGTCAATCCAAGGCTAGATAGACTTAGTGTACTCAAGAAAGGGTAGCCTGAAAATAAGGT
 TCAAATTATAGTCAGAACATAGTCAGAACATGGCAAGACAAGAGTGCCTGCTGCCGAATTGATATCAAGCT
 TATCGATACCGTCGACCTCGAGGGGGGGCCGGTACCCAATTGCCCTATAGTGTGAGTCGTTACCAACTTAAT
 GCCGTCGTTTACAACGTCGTACTGGAAAACCCCTGGCGTTACCAACTTAAT

SEQ. ID. No. 5

41.1 1288 bp
 60 GAGGGCAGCGAGAAGGAGAAACCCCAAGCCCTGGAGCCCACATCTGCTCTGAGCAATGGGTGCGCCCTGCCAA
 CCACGGCCCGGGCCCTGCCATGCATCAACCCACTCAGCGCCCTGAGTCCTGCTGAACAATCACTTGGGCAAAG
 CCACGGAGCCCTTGCCTCACCTTCTGCTCCAGGCCAAGTCAGAACACAATTCCATGTCACATGCCAAAGTCGAAT
 CTCATGTCATGGACAAGCCGGTCTTGAGTCCTGCTCCACAAGGTCAAGCCAGCGTCCAGGGCGTACCTGTT
 TGAGAACAGCGATCAGCCATTGACCTGACCAAGTCCAAAGCAAGAACAGCCAGTCCTCGCAAGCACAATCTT
 65 GTATGCTCCACCTCAGAACGACGCTCTGTCGACATGCCGACATGGTCAAAGTCCTCCCAAAGGCCACCC
 CCAAGCCAGCCTCTCCAGGGTCCCCCATGAGCTGGAAATGGATGTCAGGCGCTTGAGGATGTC

CAGTGAAGTCTCAACTTGATAAAAGAAAAGGCCGGCAGTCCAACGTGAATCCTCAGCATCTCTGATTCTAC
 AAGCCCAGTTGCCTCGAGCCTCTCCAGACATCAGAGGGCAAATACCTGCTGTGATCTGGGCCAACAGAG
 CGTATGCAAATCTCTAAGTTACGGGACTCTCAATGACCACATCAGTCAGTGGCTGGCCAACGTCAAGTACCA
 GCTTAGGAAAACGGGCGGGACAAAATTCTGAAAACATGGACAAAGGCCACCCCATCTTTATTGCAAGTGA
 GTGCCCTCCAGTCAGAACCCCTCTACCTACATCAGTCAGTCACTTGAATCTCACCTGGGTTCCAATGA
 ATGACCCGCTTGTCAAGTGGACCAAGCAAGGAGGAGCAAGAGATCTCCGGGTATCGTCGGCTCAGAGGTC
 TCCAGAAAACAATAGTGGCAAGAGGACACAGACTAAATTCAAGTGTAAAGTTGTGCTGTGGACATTGTGA
 GCAAAACATGCGTAAACCTCACCTAACGAAAACGACAGCAAGTCACCCGAACACCATTACAGTTGTAA
 GACGTGGATGAGAATAGCTCTGCAGGACGAATGCCTAGTTCCACTTCCAGCCTGGATCCCACACTGA
 ACCCTTCTCGTGCACCATCTGTCACATTGAACCTCCTCTGACACCCTGGCTCTGAGAA
 GACTGCCAAAAAATTC

SEQ. ID. No. 6

GCAP 2820 bp

15 ATCCTAAGACGACAGCCTGGAAAGCCAGCACTGGGAAGTGGTCTGAGGGATGTGGTCACTGGGTGAAGG
 TGGAGCTTCAGGGTCTCCCTCAATGAGCTGAGTTCTTGGCAGGAATTACAGCTGAAGAAAGCCTG
 CCGGGAGAGCTCAAACAGCAAGGCCAGCTGCTCACACCCGAGGAGGTGCTGGACAGGATCTCCTCCTGG
 TGGATGAGAATGGAGATGGTAAGAGGGCAGAGATGGGAGAGTGTCTCCACTCTGCATCATGCCACTTCT
 GGCGCACGTCCTGGCAAGGCCCTCACCTCAACCCCTGGGTCCTCATCTGTGAGAAGGCTGTGGAGAAG
 20 ATGTCATGAACTAACAAAGGGACTCATGAGCACGTGTTGTAGGAGTGAACAAAAGTCTCACAGGAGTTGCTGA
 TGGAGGCCAGGCACGACAGAATAGAAAGAATAGGAACCTTGGAGTCAGGCAGGGAGTGATATAATTGAGCTTC
 TCCTAGTCTCAATTCTCATCTGGAAAATGGGATAATAATAGTGGTGTAGAGGAAATGAATAGGATAATGTGT
 TTAAGAGCAGGCATAGGGTAGACCTCATTAGGCTGTTGGCTTCTCCCTGTAGGCCAAAGGCCAGGCCATT
 AGGGCTATGTGGGGAGAGAGCTGGCTTGGAAATACACACTTGGAGGCCCTCAGCTCTCAGCTCCACCCAGCATT
 25 TCCGGTGTACCATGCGAAAAGTAAACCTCAATTCTCATCAGCAAAGAAAGCCCCTAAAGGGCAGGAGACTC
 CTGGAGATTCTAGCACCTGCAAGGCCAGCTGAGACTGAGGATAGTTGGCATAAGACGTGTAG
 GCGCATCTGGGAGCGAGGTCTCTCCCTGCCAGACCCAGGTCTCCCTTCTACATGACCACCTCTC
 CTCCCCCTGCTCAGGCCAGCTGTCTGAACGAGTTGTTGAAGGTGCCCTGGACAAAGTGGGTGATGAAG
 30 ATGCTGCAGATGGACATGAATCCCAGCAGCTGGCTCGTCAGCAGAGACGGAAAGTGCCATGTTCTGAGGAGT
 CTGGGGCCCTCCACGACTCCAGGCTCACCCAGGTTCCAGGGTAGTAGGAGGGTCCCTGGCTCAGCTGCTC
 ATGCCACACTCTCCCTGGTGTGACTTCTGGCACCCCTGTGCAAGGGCTGAGTGGGATGGGAAGGGCTGC
 TGGGTTGAAGTGGCAACAGGGCATAGTCCATTGGAGGACTCCCTGGGATGGTGAAGGGAAATTCA
 35 TCTCAGTGGAAAGGCCAAAGAGCAACTGAGGGTGAGGGTCCCACAGGAAATCAGAAATGAGAACACA
 GGTAGGAGGAGGGGTGGGGAGGTGTTGAGACTGAAGAAAAGCAGGAGTTGCCGGGCAGGGCTCACGCC
 GTAATCCCAGCACTTGGGAGGCCAGGGCGAGATCACCGAGGTCAAGGAGATCGAGACCATCTGGCTAACAC
 GGGGTGAAACCCGTCCTACTAAAAATCACGGGGTGAGGTGGCGGCCCTGAGTCCAGCT
 ACTCAGGAGGCTGAGGCAAGAGAATGGCGTGAACCCCAGGGGCCAGCCTACAGTGAGCCGAGATTGCC
 40 TGCACCTCCAGCCTGGACGACAGTGAAGACTCCGCTCTCAAAAAAAAAAGAAAAGAAAAGCAGGAGTT
 TGGGGGGCAGGGGCAGCAATAATTCTATAACTTCCGGGATGCTGAGGGCGTTCATGGGAGGACCCCTGGC
 CCTCTCCCTCCAAAGGCATCTCACCGAGGTCAACAGGAAAATGGCAGCAAATACGCTGCAAGGCTGTT
 TTCTGCCTTGTGAAAGGGTCACTTAAAGGGACTGTTCTGGCTGGGCTCTGGGACCTCC
 TGCTGCCAACCCACACTCCCCAACATCTCTCTTCCATATCCCCAGTATGGACCTTCCACACTC
 CCAGCCATAAGCTGAATGTTCTCTTAAAGGATGGAGAAAACATTCTGTCTGTCTGGCAAGAATTGGGGAC
 45 TGTTGACTGGGATTGTGGGCTGGCTGGCTTAACGTGCTGTGACCCAAGACAGCCACTCTCCTCCCTAA
 CCTTGGTTATGTCCTGGCAGCACAGTGGAGCAGGTGGACTAGGCGAACAGTTGGATTATTGTT
 GTGGAATTATTTTGTATATAAAACTCTTATGTGTAACCCAAATATAGAAACTAGATTAAAAGGGAGTCT
 TGTTGAAAGGGAGCTGAGTACCTCTGGAACTGGAGGCACCTCTGAAAAAGCAAACAGTGA
 50 TGGGTCACTGTTACTCTCTATAAGACAGTTAAAGTGAAGACCTGGAAAACATTGCTTACCTTGAATAGATAG
 GTTTTTATGTTGGTATATAAGAAATAAAACTAACCTATTAAACCTGAGACTTACAGGTGTGTTATT
 ATAGTCATATAAAATTTCTCTAGACATCAATTAGTAAAGGAAATAATTGATTAGGAAATAATT
 CAGCAGCTCACACCTGCAATCCCAGGACTTGGGAGGCCAGGGCTGGATCACCTGAGGTCA
 ACCAGCCTG

55

SEQ. ID. No. 7

1b4 1205 bp

GCGCGCGTGAAGTCCGCCCCCCCAGTCACGTGACCGCTGACTGGGGCGTTCTCCACTATCGCTTACCTACCTCC
 CTCTGCAGGAACCCGGCGATATGGCTGCCCTGCCCCGGCGCATTCTCTCCCTGGCTCTCCCTCTCC
 60 TGGGCTCTGCTCCTCTCCGCTCCGATGGCGCAGCGCCCTGCAACCCAAGGCCCTTCCCTGGATACGG
 TCACCTTCTACAAGGTCACTCCAAAAGCAAGTGTGAGTCACTGGACACCCAGTACCCCTACGGTGAGA
 AGCAGGAGTGAAGTCAAGCGTCTCTGAAAACCTGGCTCCAGCGATGATCTTGGTGGCAGAGGTGGGATCT
 CAGATTATGTGACAAGCTGAGGACTGAGTGAAGAAATACAAGCTGGACAAAGAGAGCTACCCATCT
 CCTCTCCGGGATGGGACTTTGAGAAACCCAGTCCCATACAGTGGGAGTTAGGTTGGAGCCATCCAGCCTG
 GCTGAAGGGGCAAGGGGTCTACCTAGGTATGCCCTGGCTGTATACGACGCCCTGGCGGGGAGTTCAAG
 CAGGGCCTCTGGTGTGGAGGCCAGGCCCTTGAAGCAGGGCAAGATAACCTCTCAAGTGTGAAGGAGAC

TCAGAAGAGTGGCCGAGCAATACCTGAAGATCATGGGAAGATCTTAGACCAAGGGAGCAGTCCAGCATCA
 GAGATGACACGGATGCCAGGCTATTGAGAAGAACAAAGATGAGTGCAGGAGAAGGGAGCTGAAAAAGGCTGTGATTTC
 TAAACATCCTGACTGCCCTCCAGAAGAAGGGGGAGAAAGCTTAACCTGCTGCTGTGANTCCCTGTGGAATATAAGGGGYMS
 5 CAGGGTTTGGTGGGGTAGGGAGGGANACTTAACCGATTCTGACGCCCTGAGTATGCCGACATTGATGCTAACATGACCAGTCT
 KGGGAAAAGWGCTACTAACCCACGATTCTGAGGCCACTTACTCAGGTGGCTGGTCAAATGACACCTCAGAAGGA
 GGGATGCTCTAGCTGGCTGGGATAGCTGGACACTTACTCAGGTGGCTGGTCAAATGACACCTCAGAAGGA
 ATGAGTGCTATAGAGAGGAGAGGAGTGTACTGCCAGGTCTTGACAGATGTAATTCTCATTCAATTAAAGT
 TTCAGTGTGGTTAAGTGG

10 SEQ. ID. No. 8

20sa7 456 bp

GAAATCAGAAGTTAATATGACACAATTAAATATTTGTATATCTCACACCGGAGNTCTCTCAAACATAAG
 GAGTTAGAAATTACAAGTAGGCATATGCTTCCTATATTCAAGATAAATTCAATTTCGATTAATTAAATTCCAGATA
 15 GAGAGAAGTAATTTCGGAAAAGAAATGATAGCTATAATTAAAGCAGATATTCAATTACAATACCATGTAGAGACA
 TAAGCAATATTTCGGCATCATTCTGTCGCTCAGTAGGCCGTGTTCTGGTAGGGCCTTGGAGAGTACCA
 TCTATCTAAGATGGAGGAATGCTGTGGGAAGGGGGATGGAGGTGCGTTCTACGCTGAACCCCACACAGGA
 AATCTCAGGCCACACAGCTGCCCTGCGCCCTCATGTGATCATCCTGGTCAATGAAGTGAATTGCTCTA
 TTTCNGGGGGT

20 SEQ. ID. No. 9

Genomic Sequence Encoding ZABC1

CCATCATATTCTATTTTGGCGGAGAGGGAGACTTGCTCTGTCGCCAGGCTGGACCAGTGGTGCATCT
 TGGCTCACTGCAACCTCCACCTCTGGTTCAAGTGATTCCAAATAGCTGGGATTACAGGTGTATTACCATGC

25 CCAGCTAATTTCGTATTTAGCAGATAAGGGTTCCACCATTTGGAGTATAAGCTGTGAGGCCACTATAACCCCTC
 TGATCCACCCACTTCGGCTTCCAAAGCATTGGAGTATAAGCTGTGAGGCCACTATAACCCCTC
 ACAGTTTCACGTATTAGTCAAGTTCTAAATACAGTAATAATGTTGAGAGCTGACATAGGGACTAACTGGTTT
 TTTTTTTTTTTTCAATTCTACTGAACTTGATTTCTAAATAAGGACATTTAAAAAAACAAAAA

30 AACTCCACTATTGCCATTGCCACTATTGATTTAAAAATAAGCTATTAGCATCTAAAGTAGGAAGGA
 CCTCAAATAATGAGCTTGTCTTGGCAGGGAAAACAGCCTGTCAGAATTGATAACTGTTCTAGGGTA
 TGTGCTGTTATTCAAGTAAACCTTGCCTGGACGCTAGCATTCAAGTAATAACTTGTGAGAATAAGCAATGAAACT

35 TAAGCTTCTATGTATAGAAACCTAAGTCACCTCACATTCTGATAGCAGAGTAATTGAATATTCTTCAATGTT
 AGCTCTATCCCCAACACAGAAATTTGGACTGTAAGGCCATCTTACAGTTAAACCAACTGGCTTAAAGATAG
 AATGAAAGATGGTATGGCAGTGACACTTGAAGGGTGTGACTAGAACACTGGGCTCTGGAGTGTCTTATT

40 TATCACACCAAGCTGGTACCCAGGGCTTGTGATCCTCATTGTGATAGCAACAAAGAAAAGACTCAGGACAT
 TCTTCTTACCTTAATCCTGATCTGAGTCTTATTAGAAAAGCTTAATGTTAAAGATCTAGTTATTCAAAA
 CTAAAGATAACAAGGAGTATGAGAAATTCTATTGGACTGTAAGGGAGAGTGTCTTGGCTCTGAGCC

45 TGAGGCCCTCCTGCTTTAAGGAAGTAGAGAGAGGGAGGAAAGTAAGTATGCTTTGTTTAAAGGTACT
 TTGCTGGAGTAGTTGCATGCCCTTGGTTCTGGGTGAAATTAACTGACTTAAGTTAAAGTAGTTGGGACT
 ATTAAAAACAATGCCATCCAATGTTGCCATAAAGCAGAGGGTATTGGCTTAAAGTTAATTCTCAGG

50 AGTAAAATTAGCTTCTAAACCAGAAGCAGCAGAGCTAAATAAGTAATTCTCAGGCTGGCAGTGCATGATGTGA
 AAGGTAGATTAAAAAAATGAGAGGGCCATTCTGATGAAAGACTAAAGCCATGTTGAAACAGCCTGTTGAGGAT
 TTATTAAATCTATACATTACAAGGAGCTTCTGATGCTCTTCTCTTCTATTGTTGTTGACTAGGAAGCCC

55 CACCCAGTCTTGTGAAGGAGAAAGCTGTGAAAGCAAGCTGGGATTGAAACAGTGGATTGAGGTTCAAT
 CCAGTAACAAAATATATCAGGTTCCCTGGCCAAGATGAGTGCACATTCTGAGGTGTTAAGTATTCTGAAT
 GGGGATTTTAGGAAAAGTTCTGTATTCTGCTCATTTGTTGACCTCTGTATGTGCAAATCTAAGGGGT

60 GTTGGCCACTTAGATTCTGGATGCAAGATTGTTGATATGAAACAAATTAAATTGTTGATACACTGG
 ATTAAAAATAGTTACTAAAGTTTAATTCTCATCTTAATTTCACAGTTCTATAGTCTTGTGTTAGTTAGGG

65 AGGCTGTTGATGGCATCCACATGTGCATTAGTGGCATTAAATGTTACAGTCAAGTCAATTAAACAAATTCTGACC
 TAAAACCTGACATTAGTTAAGTGTGCTTAAAGCACTGATTAAATGGGATTAAACTGGATGAAATTCTGATT
 AATAAGTGTACTGACTGGATAAAATGCCAATGATTAAATCAAGCACGTTAACAGGATGCCCTATATATTAGT

TAAAGTGAAGCAATTAGATTAGTACCTCTCTGCTCGCTGGAAAAGACCGTATGACTCACCCACACCAGCCTC
 TCTCGCTCTGAGTGTAGCTAACCGTTCTGTTCTCTCTAGGGTTGGAAATCCTGTCAGGTTGCT
 70 GGGATTGACTTCTGCTCAATTGAAACACTCATTCAATGGAGACAAGAGAAACTAATGCTTGTGCTGATTCTAT
 TTGAATGAGGCAATTGGAAACCTGTATGCCCTGTTGTTGAGAACCAGTGACACCACACTGAGCTTCTAAA
 AGTTGAAAGAAGTTAGAGGACTATACACTTCTTTGAACCTTATAATAAAATTGCTCTGGTTTGGAAACCC

75 AGGGCTGTTAGAGGGTGAGTGCACAGGAAACATGCCAACTCAATTCTCTTAATGTCATGGATGGGCAAGAAGT
 GAGATTATGCAATCGAAAGTGCACAGGAAACATGCCAACTCAATTCTCTTAATGTCATGGATGGGCAAGAAGT
 80 GATTGGCAGCTCTTGGCAGTCCGATGGAGATGGAGGATGCCCTGTCATGAAAGGGACCGCTGTTGTTCCATT
 CGAGCTACACAAGAAAAAAATGTCATCCAATCGAGGGGTATATGCCCTGGATTGCTGATGTTCTGAGCCAGACCT
 TCACACATTCAAGAACCTTAATAACATGCTTAACTGCAACACCCGGCCTACCTCTGTGAAACCAGCAGTCTCG
 GGTTGAAGCAGAGTATCTCAGTCCGCTGATAAAAGTCAAGTGCAGAACAGAACCTCCAAGGAAAAGAATTGCAAG

85 GAAAATGAATTAGCTGTGAGGTATGTTGAGACATTTAGAGTCGCTTTGATGTTGAGATCCACATGAGAACAC

90 ACAAAAGATTCTTCACTTACGGGTGTAACATGTGCGGAAGAAGATTCAAGGAGCCTGGTTCTAAACATACAT

95 GCGGACACATAATGGCAAATCGGGGCCAGAAGCAAACCTGCAAGGCTGGAGAGTAGTCCAGCAACGATCAAC

ACACAAAGATACTCAGGATTCATAAAAATGCAGCTGATGACAGTGCTGATAAAGTGAATAAAAACCCTACCCCT
 GCTTACCTGGACCTGTTAAAAAAGAGATCAGCAGTTGAAACTCAGGCAAATAACCTCATCTGTAGAACCAAGGCCG
 ATGTTACTCCTCCGGATGGCAGTACCCACCCATAACCTGAAAGTTAGCCCCAAAGAGAAGCAACGGAGACCG
 5 AGCTGACTGCAGATAACAGGCCAAGTGTGGATTGTACGAAAAAAACCTTAAATTATCCGTGGGGCTTCAACAT
 TGCCCCGCAATTCTTGTAGTAAAAGTTGATTCCAAGTATCACCTGTCCATTGTACCTCAAGACATTATC
 CAGAAGTTAAATGATGCCAGAGACTGGCAGATAACATACCTGACGTTCAAAACTGTGCTCCCTCCAGTCTGT
 CTTGCTTAGAAGTCACGTCAGCTCCGGATGCCAGCTCCAGTCCAAATCCCTGCCATCTGCAAGGGGAAGCAGGCC
 10 AAACCCAGGCCAAGTCTGCTTCCGGCGAGTCCAAATCCCTGCCATCTGCAAGGGGAAGCAGGCC
 GGCCAGGCCAGGGCCCTCTGACTTCAGGGATAGACTCTAGCACTTAGCCCAAGTAACCTGAAGTCCCACAGACC
 ACAGCAGAAATGTGGGGTCCAAGGGGCCACCAGGCAACAGCAATCTGAGATGTTCTAAACCAACAGTGT
 CCTGCACCGGATAAGACAAAAGACCCGAGACAAATTGAAACCTCTCCAGTAGCTCTCTCAGGCCACCC
 GCAGCAGTAACATCAATGGTCCATCGACTACCCGCCAAGAACGACAGCCGCTGGGACCTCCGGGAAGGACTA
 TTTCTGTAATCGGAGTGCACAGCAACTATGCGAGCAGAAATTGGTGAAGGGCTATGACACTTCCAAAGTAC
 15 CCAGGCCCTTGACCTGAGCAGCCGGGCCATTACAGAAGAGGCTATGACCTTCCAAACCAAGGTTCTGAGCTC
 GCATCACATCACTGTTACCGCAGGACTGTTGATCCGTGAGCGCTGCCCTCCAAACCAAGGTTCTGAGCTC
 CAGCGAGGTCGATTCTCAAATGTCAGTGTCAAGGCCCTATGGTGCCTCCGGGCCACTTACACTTGTGT
 CCTGCTGGTAGTCAGCATCCAGCTGAGCAGTAAAGGTTGATTCATGAGGGGCGCTGTGTTAAATGGCTGCC
 20 ACTAGTAAATAGCTAATCCAGGCATTCTCAGTGGAGATGGTACCACTCCAAAGGGTGGGGTAGGCAGCCAGAAG
 TTCTGGGGTCACAGAGAGAACGATTCTAGATAACGGCAGTGGTTGTGTCCTCAAGGCTTACTTAACCTGT
 GGGTTAACTCTAACCTGTGTATTATTCTTTGATTTGTTAGTCTACTTATTAGAGAAGGGTCT
 GCTCCGTATCTAGATTGGAGTGCAGGGTGTAAATCATAGCTACTGTAGTCTGAAATCCTGAGTTCAAGAGATC
 CTTCTGCCAGCTCCAGGGTAGCTGAGACTATATGTGTCGTCACATGCACAGCTGATTAAATTNTTT
 TAGAGATGGAGTGCCTCCAGGGCTGGTCTGAACCTCCGCTGAGGTGATCCTCTGCGTTGACCTCCAAAGTAC
 25 TAGACTACAGATGCACTCCACCCACGCTT

SEQ. ID. No. 10

ZABC1 Open reading frame

ATGCAATCGAAAGTACAGGAAACATGCCAACTCAATCCCTCTTAAATGTACATGGATGGGCCAGAACGTGATTGGCA
 GCTCTTGGCAGTCCGATGGAGATGGAGGATGCCCTGTCATGAAAGGGACCGCTTGTGTTCCATTCCGAGCTAC
 30 ACAAGAAAAAAATGTCATCCAAATCGAGGGTATATGCCCTGGATTGTCATGTTCTGAGCCAGACCTTCACACAT
 TCAGAAGACCTTAAACATCTGTTAAATGCAACACCGGCCCTACCTCTGTGAACCAGCAGTTCTGGGTGAAG
 CAGAGTACTCTAGCTCCGCTTGATAAAAGTCAGTGCAGACAGAACCTCCAAAGGAAAAGAATTGCAAGGAAAATGA
 ATTAGCTGTGAGGTATGTGGCAGACATTAGAGTCGCTTTGATGTTGAGATCCACATGAGAACACACAAAGAT
 35 TCTTCACTTACGGGTGTAACATGTGCGGAAGAAGMTSRRSSAGCCTGGTTCTTAAACATGCGGACAC
 ATAATGGCAATCGGGGCCAGAACGAAACTGCAGCAAGGCTGGAGAGTAGTCCAGCAACGATCAACGAGGTCT
 CCAGGTGACCGCCGAGAGCATCTCTCCTTACAAATCTGTCATGGTTGTGGCTTCCATTTCACAAATAAA
 GAAAGTCTAATTGAGCACCGCAAGGTGACACCAAAAAACTGCTTCCGAGTACCCAGCAGCCGAGACAGACTCTC
 CACAAGGAGGAATGCCCTCGAGGGAGGACTTCTGAGTGTCAACTTGAGACCAAAATCTCACCCCTGAAAC
 40 GGGGAAGAAGCCCTGCAAGTGCATCCCTCAGTCGATCCGTTACCACCTCCAGGCTTGGCAGCTGGTACCCAA
 GAAAAGTGGCATTGCCAAGAAGTGAAGGAATCGGGCAAGAAGGGAGCACCAGAACGAGGATTGAGTTCCG
 AGAAGGGAGCTTGAGAAACAAATAAGGGCAGTTGTCAGGCCCTCGCAAGAGAACAGGAAAGTCAAACACTCCA
 CGCGAAGCGCCCTCGTGACGCCGATCCCAAGTTACCCAGTAGCAAGGAGAACGCCACTACTGCTCCGAGTGC
 GGCAAAAGCTTCAGAACCTACCACCAAGCTGGTCTTGCACCTCAGGCTTACAGGCTGGCAGCTGGTACCCAA
 45 AGTCGCCACCAGTCTGTGGACGGAGGCAGCCGGGAGCTGTTCTCTGACCTCGCCGCCCTCTGGATGAAA
 TGGAGCCGTGGATCGAGGGGAAGGTGTTCTGAAGACGGATCTGAGGTGGGCTTCCGAAGGAATCCATCTGGAT
 AAAATGATGATGGAGGAAAAAATAAAACATCTTACATCTCAAGAGAGTGTAGTTATTGAAAAGTTTCCGTT
 CAAATATTACCTCAATTACATCTCAGAACGATCACAGTGAAAACCATACAAATGTAATTGTAATATGC
 50 TGCAAGCCCAGAACATCTGAGGTACTCTGAGAGACATCACAGGAAAACAAACCGATGTTGCTGCTGAA
 GTCAAGAACGATGGTAAATCAGGACACTGAAGATGCACTATTACCGCTGACAGTGCAGAACCAACAAAATTGA
 AAAGATTTTGATGGTGCCTAAAGATGTTACAGGCAGTCCACCTGCAAACAGCTTAAGGAGATGCCCTCTGTTT
 TCAGAATGTTCTGGCAGGCCCTGTCCTCACCAGCACACAAAGATACTCAGGATTTCCATAAAATGCACTGAT
 GACAGTGCATGAAAGTAATAAAACCTACCCCTGCTTACCTGGACCTGTTAAAAAGAGATCAGCAGTTGAAA
 55 CTCAGGCAAATAACCTCATCTGAGAACCAAGGCCGATGTTACTCTCCCTCCGGATGCCAGTACCCACCAACCT
 TGAAGTTAGCCCCAAAGAGAACGAAACGGAGACGCCAGCTGACTGAGATACAGGCCAAGTGTGGATTGTCAGGAA
 AAACCTTAAATTATCGTGGGGCTTCAACATTGCCGCCATTCTTGTAGTAAAGGTTGATTCAGCTTCTGTTT
 TCACCTGTCCATTGTCACCTCAAGACATTATTCAGAAGTTTAATGATGCAACAGAGACTGAGCATAAAATA
 CAATCTGACGTTCAAAAACCTGTCAGAACAAAGTCTGCTTAGAAGTGCAGTACCGGATGCCGCCAGCGTTG
 CTGGGAAAAGATGTGCTCCCTCTAGTTCTGTAACCCAAAGGCCAAGTCTGCTTCCCGGCCAGTCCAAAT
 60 CCCTGCCATCTGCGAAGGGGAAGCAGAGGCCCTCTGGGCCAGGCAAGGCCCTCTGACTTCAGGGATAGACTCTAG
 CACTTAGCCCCAAAGTAACCTGAAGTCCCACAGACCACAGCAGAACATGTGGGGTCCAAGGGGCCACAGGCCA
 CAGCAATCTGAGATGTTCTTAAACCCAGTGTTCCCTGCAACGGGATAAGACAAAAAGACCCGAGACAAAATTGA
 AACCTCTCCAGTAGCTCCCTCTCAGGCCACCCCTGGCAGCAGTAACATCAATGGTTCCATGCACTACCCGCCAA
 GAACCGACAGCCGGGGCACCTCCGGGAAGAGACTATTCTGTAATCGGAGTGCAGGCCAATACTGCAGCAGAATT
 GGTGAGCCCCCTCCAAAAGACTGAAGTCCACGGCTGGTCCAGCTGAGCTGAGCAGGCCAGGGCAATTACAGAA
 65 GAGGCTATGACCTTCCCAAGTACCATATGGTCAGAGGCATCACACTGTTACCGCAGGACTGTGTGATCCGTC
 GCAGCGCTGCCCTCCAAACCAAGGTTCTGAGCTCCAGCAGGCCAGTCTCCAAATGTCGACTGTTCAAG
 CCCTATGGTGGCTCCGGGCCACTTACACTTGTGTCCTGCTGGTAGTCCAGCATCCAGCTGACGTTAGAAGGTC
 TTGGTGGATGTCAGTGCCTACTCCCCATGAAATTAAATTACTTCATCCTTGAGAAGCGAATGGTAAAGCTAC

TGAAATAAGCTGTGATTGTACTGTACATAAAACATATGAGGAATCTGCAAGGAACACTACAGTTGTAA

SEQ. ID. No. 11

ZABC1 Protein

5 MQSKVTGNMPTQSLLMMYMDGPEVIGSSLGSPMEMEDALSMKGTAVVPFRAEQKNVIQIEGYMPLCDMFCSQTFTH
SEDLNKHVLQMHRPLCEPAVLRVEAEYSLPLDKSQRTEPPKEKNCKENEFSCVECGQTFRVAFDVEIHMRTHKD
SFTYGCNCGRXXXXPWFLKNHMRTHNGKSGARSKLQQGLESSPATINEVVQVHAAEISISSPYKICMVCGFLFPNK
ESLIEHRKVHTKKTAFGTSSAQTDSPQGGMPSSREDFLQLFNLRPKSHPETGKPKVRCIPQLDPFTTFQAWQLATK
10 GKVAICQEVKESGQEGSTDNDSSSEKELGETNKGSCAGLSQEKEKCKHSHGEAPSDADPKLPSSKEKPTHSEC
GKAFRTYHQVLVHSRVHKKDRAGAESPTMSVDGRQPGTCSPDLAALPDENGAUDRGEGGSEDGSEDLPEGIHL
KNDDGGKIKHLTSRECSYCGKFFRSNNYLNILRLTHGKPKYCEFCCEYAAAQKTSRLRYHLERHHKEKQTDVAAE
15 VKNDGKQNQDTEDALLTADSATQTKNLRKFDFGAKDVTGSPPAKQLKEMPSVFQNVLGSAVLSPAHDQDFHNAAD
DSADKVNKNPRTPAYLDLLKKRSAVETQANNLICRTKADVTPPDGSTTHNLEVPSPKEQQTETAAADCYRPSVDCH
KPLNLNSVGLAHNCAPAISLSKSLIPSITCPFCFTKTFYPEVLMMHQRLEHKYNPDVHKNCRNKSLLRSRTGCPPAL
LGKDVPPLSSFCKPKPKSAFPAQSKSLPSAKGKQSPPPGPKAPLTSGIDSSTLAPSNLKSHRPQQNVGVQGAATRQ
QQSEMFPKTSVSPADPKTRPETYKLKPLPVAPSQPTLGSSNINGSIDYPAKNDSPWAPPGRDYFCNRSAANTAAEF
GEPLPKRLKSSVVALDVDQPGANYRRGYDLPKYHMVRGITSLLPQDCVYPSQALPPKPRFLSSEVDSPNLTQVK
PYGGSGPLYTCVPAGSPASSSTLEGLLGCQCLLPKLNFTSSFEKRMVKATEISCDCTVHKTYEESARNTTVV

20 SEQ. ID. NO. 12

1b1

GGAAACAGCTATGACCATGATTACGCCAACGCTGAAATTACCCCTACTAAAGGAAACAAAGCTGGAGCTCCACC
GCGGTGGCGGCCCTCTAGAACTAGTGATCCCCCGGCTGCAGGAATTCCGGCACGAGGCTCCACCGACAGCAGG
25 CACTGGGAGCACGCACTGGAGACCCAGGACCCCTGTGCAGGAGCAGCTCCGGGTGACACGAGGGACTGAAGATA
CAGAAGCAGAGACTTACCAAGGACAACCGCTCTGCTCTGAAACGGGTTCCAGTGGTGGTGCACCCACACAGTTCA
GCACTTAGAGGAAGTCGACTGGGATAAGTGTCAAGACGGATAATGTGCCACTTCTCCCCAGAGACAACCGAG
ATAAGTGTGCTGCGGATGCAACGGAAAGAATCTGGGAAAGAGGCCAACCCGAGGACCCAGCTGCTAAATCTC
30 GTTTTTCTTGATGCTCTCTGGCCTGTACCCAGGACGTACCCAGGAGACAGCTGGGAGACCAAGCCGAGATTCA
GAAGCTTGTGCTCAGCTCCAAATAAGCTCAGGAAACAGAAGACCCAAAGTGAAGAGCTGGACACTTCCGGTGGCAGCT
GGACCGGGCCAGGACACAGATAAACCCCCAGGGCACGCCGGGCCAACAGACAAGGTCCTCTGCCAGGGATC
CCACGCTCTCCCACCTGAGACAGGGGAGCAGGAGAAAGGTGCCAGGTGACAGCCAACAGGAAGCCAAGAGGGCAGAGCAT
CAAATTCTCAAGCTGGACAAGGGACAGGAAAGGTGCCAGGTGACAGCCAACAGGAAGCCAAGAGGGCAGAGCAT
40 CAAGACAAGGTGGATGAGGTTCTGGCTTATCAGGGCAGTCCGATGATGCCCTGCAAGGAAGGACATAGTTGACG
GCAAGGAAAAGAAGGACAAGAACTTGGAAACTGCCGATTGCTCTGCTCCCTGGGGACCCAGAAGGACTGGAGACTGC
AAAGGACGATTCCCAGGCAGCTATAGCAGAGAATAATAATCCATCATGAGTTCTTAAAACCTGTTTCA
CCTAACAAAGCTGAAACAAAAAGGCCAGAACAGACCGGGCTGAAAGACTCACCACACTCAGCTGACCTTA
AGTCAGACAAAGCCAACTTACATCCCAGGAGACCCAAGGGGCTGGCAAGAAATTCAAAGGATGCAACCCATCGG
GCACACACAGTCCGTGACAACCCCTGACACTGCCAGAGCCTGCAAGGAAGGACCCAAGGAGAAATCAGGACCCACCTCTGCC
45 CTGGGCAAATGTTGGAAAAAGTCAGTTAAAGAGGACTCAGTCCCCACAGGTGGGAGGAGAATGTGGTGTG
AGTCACCACTGAGAGATTATAAGTCCAAGGAAGTGAATCAGCCTTACAACAGTGGACCTCAACGAAGGAGATGC
TGCACCTGAACCCACAGAACGAAACTCAAAAGAGAAGAAAGCAAAACCAAGAACCTCTGATGGCGTTCTCAGA
CAAATGTCAGTCAAAGGGGATGGAGGGATCACCACACTCAGAAGAAATAATGGGAAAGACTCCAGCTGCCAACAT
CAGACTCCACAGAAAAGACTATCACACCGCCAGAGCCTGCAACCAACAGGAGCACCACAGAAGGTTAAAGAGGGCTC
50 CTCGAAGGACAAGAAGTCAGCAGCGAGATGAACAAGCAGAGAACAGCAACAGCAGGAAGGCCAACAGCAGGCCAG
TGCACAGAGCAGGCCACGGTGGACACAAACTCAGTGCAGAATGGGACAAGCTCCAAAAGAGACCTGAGAACGG
AGCAGTCCCTGGGGCTTCTTAAAGGCTGGGACCAAGGGATGTTGGATGCTCAAGTGCACAAACAGACCCAGT
ATCCATCGGACCAGTGGCTGCAAACCCAAGTAACAAATCAGCACGGTCTCCACCAAGGTTCTCTGCCACCAAGATGT
GTTCTCTTACTCCATCTCTCCCCAACACGCTCCATGTATATATTCTCTGATGGCAGCAAATGAAATTCTGC
55 CTAGAAATTAAAGCCGAGCTGTTGATATTGAGGTGATTATTACGTCCTGGTCAGTCTTTCTGGCAAATAA
CAGTAAAGATGGTTAGCAGGTACCTAGTTGGGTGAGAAGAGTCGATGATCACAAGCAGGAAAGGGAGGAAATA
GAGGAATGTGTCGGGTTAAGTGTGAAATGGCAGTGGTGGCCGGCGTGGCTCTGCCCTGTAATCTCAGCA
CTTGAGGGCCAGGGCAGGTGGATCACCTGAGGTCAAGACTAGCCTGCCAACATCATGAAACCCCG
TCTCTACTAAAATACAAAATTAGCCAGGCATGGTGGCACACACCTGTACTCCCAGCTACTCGGGAGCCCCAACGC
60 ACGAGAACCGCTGTACCCAGGAGGTGGAGGTGGCAGTGGAGGGCAAGTGGCAGGAAAGTGCACCATGCACTCCACCC
AGAGCAAGATTCTATCAAAAAAAAAAGGCAGTGGCAAGTAAGTTATAAGAGAAGAAATGCTGCTAGAAGGAATTAAG
CGTTGAGTAAACCGCTGCTCATCTCTAAGCTGAGAAGGGAGACGAAAATCCATTGTTAAATTCACTCTC
AAGGAGGGAGAACCCGGGCTGTTGGGTGGCTGCAATTCTCTAGAACCGAATGTGTTGGGTATAGAAAAAGGAA
TGAATAAGCGTTGTTTCAATAGGGCTCTGTAAGTTATTGAGAGAGGGAAAAGATTGACTGGGGAGGGCTTA
AAATGATTGGGAAAACAATTGCTTTGAGGCTCAGTGACAACGGCAAAGATTACAACCTAAAAAA
AAACTCGAGACTAGTTCTCTCTCGTGCCTGAATTGATACGCTGACCTCGAGGGGG
GGGCCGGTACCCAATTGCCCTATA

SEQ. ID. NO. 13

Genomic Sequence from BAC clone 97

Filtered query sequence:

>query_seq

5 TGTGATATTGATTCATGCCCTCTGCACCTGCCAAACATCACACGCTTG
 CCATCCAGTCCACTCGATTGGCAGTCAGATGAAAAACTGGGAACCAT
 TTGTGTTGAGTCCAGCAAGATGCCAGGACCTGCATGTTCAGAACGAAGT
 TCTTCATCATCCAATTCTCCCTGTATATGGGCTTACCAACNACTGCCGTT
 AAGTCGTGTNAAGTCACCCTCAGGTACATAATGGAATAATTCTGCAAAG
 10 GCAGGAGNCACTTCTCTCCAGTGCTCAGACCATGAAAGTTCTGATGT
 CTTTGGAACCTTGTCTGCAAATAGCTCGAAGGAGACATGGCCTAAAGGCT
 GCCCATCTGCGGTGATATTGNAACATGGTAGGGCTGACCGTGGCTGTGGC
 CATGACTTTAGANTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
 15 NN
 NN
 NNNNNNNNNNNNNNNNNNCCAAATGCGGGACAGAGAACATCNAAGAAA
 GGGAAAGGGCCTGAGTTATGCCAAAGTTCCCAGATTGGTTCCATTG
 AAACGTAGCTCTGTGAGATACCATCAGGTGTTATGTAAGAAATGTCTGT
 GTAGTCAAATATGTTGAGTGAGTGAGCCTGAGCTGAGCAAGACTTACT
 GCAAGACTTCCCACCTTCTGTCCTTTATGCTAACGGTAACACAAAC
 20 TCCAAAAGTGGGTGTACAGCATGAGGCATTAACAAAAATTATTGGACC
 CCACACACNN
 NN
 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCTCTC

25

SEQ ID NO 14

gb|M19533|RATCYCA Rat cyclophilin mRNA, complete cds.

Length = 743

30

Minus Strand HSPs:

Score = 418 (115.5 bits), Expect = 1.5e-58, Sum P(5) = 1.5e-58

Identities = 96/112 (85%), Positives = 96/112 (85%), Strand = Minus / Plus

S = rat CYCLOPHILLIN; q = SEQ ID NO 13.

35 Query: 372 TNCAATATCACCGCAGATGGCGAGCCTT TAGGCCATGTCCTCGAGCTATTGCAGAC 313
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Sbjct: 64 TTCGACATCACGGCTGATGGCGAGCCCTGGT CGCGTCTGCTCGAGCTTTGCAGAC 123

40 Query: 312 AAAGTTCAAAGACATCAGAAA ACTTTCATGGCTGAGCACTGGAGAGAAAG 261
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Sbjct: 124 AAAGTTCAAAGACAGCAGAAA ACTTCGTGCTGAGCACTGGGAGAAAG 175

Score = 236 (65.2 bits), Expect = 1.5e-58, Sum P(5) = 1.5e-58
 Identities = 52/58 (89%), Positives = 52/58 (89%), Strand = Minus / Plus

45 Query: 117 TGCTGGACTCAACACAATGGTCCCAGTTT CATCTGCACTGCCAAATCGAGTG 60
 ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Sbjct: 348 TGCTGGACCAACACAATGGTCCCAGTTTATCTGCACTGCCAAGACTGAGTG 405

50 Score = 177 (48.9 bits), Expect = 1.5e-58, Sum P(5) = 1.5e-58
 Identities = 41/48 (85%), Positives = 41/48 (85%), Strand = Minus / Plus

Query: 60 GACTGGATGGCAAGCGTGTGATTTGGCAAGGTGCAAGAGGGCATGA 13
 ||||| ||||| ||||| ||||| ||||| |||||

55 Sbjct: 404 GGCTGGATGGCAAGCATGTGGCTTGGGAAGGTGAAAGAAGGCATGA 451

Score = 154 (42.6 bits), Expect = 1.5e-58, Sum P(5) = 1.5e-58
Identities = 34/38 (89%), Positives = 34/38 (89%), Strand = Minus / Plus

5 Query: 153 AGAACTTCGTTCTGAAACATGCAGGTCCCTGGCATCTTG 116
Sbjct: 299 AGAACTTCATCCTGAAGCATAACAGGTCCCTGGCATCTTG 336

Score = 86 (23.8 bits), Expect = 1.5e-58, Sum P(5) = 1.5e-58
Identities = 22/28 (78%), Positives = 22/28 (78%), Strand = Minus / Plus

10 Query: 256 TCCTGCCTTGCAGAATTATTCCATTAT 229
Sbjct: 193 TCCTCCTTCACAGAATTATTCCAGGAT 220

15

WHAT IS CLAIMED IS:

1 1. An isolated nucleic acid molecule comprising a
2 polynucleotide sequence having a subsequence which specifically hybridizes
3 under stringent conditions to a sequence selected from the group consisting of
4 SEQ. ID. No. 2, SEQ. ID. No. 3, SEQ. ID. No. 4, SEQ. ID. No. 5, SEQ.
5 ID. No. 6, SEQ. ID. No. 7, SEQ. ID. No. 8, SEQ. ID. No. 9, SEQ. ID. No.
6 10, SEQ. ID. No. 12, AND SEQ. ID. No. 13.

1 2. The isolated nucleic acid of claim 1, wherein the
2 subsequence specifically hybridizes under stringent conditions to SEQ. ID. No.
3 2.

1 3. The isolated nucleic acid of claim 2, wherein the
2 subsequence is SEQ. ID. No. 2.

1 4. The isolated nucleic acid of claim 1, wherein the
2 subsequence specifically hybridizes to SEQ. ID. No. 3.

1 5. The isolated nucleic acid of claim 4, wherein the
2 polynucleotide is SEQ. ID. No. 3.

1 6. The isolated nucleic acid of claim 1, wherein the
2 subsequence specifically hybridizes under stringent conditions to SEQ. ID. No.
3 4.

1 7. The isolated nucleic acid of claim 6, wherein the
2 subsequence is SEQ. ID. No. 4.

1 8. The isolated nucleic acid of claim 1, wherein the
2 subsequence specifically hybridizes under stringent conditions to SEQ. ID. No.
3 5.

1 9. The isolated nucleic acid of claim 8, wherein the
2 subsequence is SEQ. ID. No. 5.

1 10. The isolated nucleic acid of claim 1, wherein the
2 subsequence specifically hybridizes under stringent conditions to SEQ. ID. No.
3 6.

1 11. The isolated nucleic acid of claim 10, wherein the
2 subsequence is SEQ. ID. No. 6.

1 12. The isolated nucleic acid of claim 1, wherein the
2 subsequence specifically hybridizes under stringent conditions to SEQ. ID. No.
3 7.

1 13. The isolated nucleic acid of claim 12, wherein the
2 subsequence is SEQ. ID. No. 7.

1 14. The isolated nucleic acid of claim 1, wherein the
2 subsequence specifically hybridizes under stringent conditions to SEQ. ID. No.
3 8.

1 15. The isolated nucleic acid of claim 14, 16, 18, 20, wherein
2 the subsequence is SEQ. ID. No. 8.

1 16. The isolated nucleic acid of claim 1, wherein the
2 subsequence specifically hybridizes under stringent conditions to SEQ. ID. No.
3 9.

1 17. The isolated nucleic acid of claim 16, wherein the
2 subsequence is SEQ. ID. No. 9.

1 18. The isolated nucleic acid of claim 1, wherein the
2 subsequence specifically hybridizes under stringent conditions to SEQ. ID. No.
3 10.

1 19. The isolated nucleic acid of claim 18, wherein the
2 subsequence is SEQ. ID. No. 10.

1 20. The isolated nucleic acid of claim 1, wherein the
2 subsequence specifically hybridizes under stringent conditions to SEQ. ID. No.
3 12.

1 21. The isolated nucleic acid of claim 20, wherein the
2 subsequence is SEQ. ID. No. 12.

1 22. The isolated nucleic acid of claim 1, wherein the
2 subsequence specifically hybridizes under stringent conditions to SEQ. ID. No.
3 13.

1 23. The isolated nucleic acid of claim 22, wherein the
2 subsequence is SEQ. ID. No. 12.

1 24. The isolated nucleic acid of claim 1, further comprising a
2 promoter sequence operably linked to the polynucleotide sequence.

1 25. The isolated nucleic acid of claim 1, which nucleic acid is
2 a cDNA molecule.

1 26. A method of screening for neoplastic cells in a sample, the
2 method comprising:

3 contacting a nucleic acid sample from a human patient with a
4 probe which hybridizes selectively to a target polynucleotide sequence
5 comprising a sequence selected from the group consisting of SEQ. ID. No. 1,
6 SEQ. ID. No. 2, SEQ. ID. No. 3, SEQ. ID. No. 4, SEQ. ID. No. 5, SEQ.
7 ID. No. 6, SEQ. ID. No. 7, SEQ. ID. No. 8, SEQ. ID. No. 9, SEQ. ID. No.
8 10, SEQ. ID. No. 11, SEQ. ID. No. 12, and, SEQ. ID. No. 13 wherein the
9 probe is contacted with the sample under conditions in which the probe
10 hybridizes selectively with the target polynucleotide sequence to form a stable
11 hybridization complex; and

12 detecting the formation of a hybridization complex.

1 27. The method of claim 26, wherein the nucleic acid sample
2 is from a patient with breast cancer.

1 28. The method of claim 26, wherein the nucleic acid sample
2 is a metaphase spread or a interphase nucleus.

1 29. The method of claim 26, wherein the probe comprises a
2 polynucleotide sequence as set forth in SEQ. ID. No. 1.

1 30. The method of claim 26, wherein the probe comprises a
2 polynucleotide sequence as set forth in SEQ. ID. No. 2.

1 31. The method of claim 26, wherein the probe comprises a
2 polynucleotide sequence as set forth in SEQ. ID. No. 3.

1 32. The method of claim 26, wherein the probe comprises a
2 polynucleotide sequence as set forth in SEQ. ID. No. 4.

1 33. The method of claim 26, wherein the probe comprises a
2 polynucleotide sequence as set forth in SEQ. ID. No. 5.

1 34. The method of claim 26, wherein the probe comprises a
2 polynucleotide sequence as set forth in SEQ. ID. No. 6.

1 35. The method of claim 26, wherein the probe comprises a
2 polynucleotide sequence as set forth in SEQ. ID. No. 7.

1 36. The method of claim 26, wherein the probe comprises a
2 polynucleotide sequence as set forth in SEQ. ID. No. 8.

1 37. The method of claim 26, wherein the probe comprises a
2 polynucleotide sequence as set forth in SEQ. ID. No. 9.

1 38. The method of claim 26, wherein the probe comprises a
2 polynucleotide sequence as set forth in SEQ. ID. No. 10.

1 39. The method of claim 26, wherein the probe comprises a
2 polynucleotide sequence as set forth in SEQ. ID. No. 12.

1 40. The method of claim 26, wherein the probe comprises a
2 polynucleotide sequence as set forth in SEQ. ID. No. 13.

1 41. The method of claim 26, wherein the probe is used to
2 identify the presence of a mutation in the target polynucleotide sequence.

1 42. A method for detecting a neoplastic cell in a biological
2 sample, the method comprising:

3 contacting the sample with an antibody that specifically binds a
4 polypeptide antigen encoded by a polynucleotide sequence comprising a
5 sequence selected from the group consisting of SEQ. ID. No. 1, SEQ. ID. No.
6 2, SEQ. ID. No. 3, SEQ. ID. No. 4, SEQ. ID. No. 5, SEQ. ID. No. 6, SEQ.
7 ID. No. 7, SEQ. ID. No. 8, SEQ. ID. No. 9, SEQ. ID. No. 10, SEQ. ID. No.
8 12, and SEQ. ID. No. 13; and

9 detecting the formation of an antigen-antibody complex.

1 43. The method of claim 42, wherein the sample is from
2 breast tissue.

1 44. A method of inhibiting the pathological proliferation of
2 cancer cells, the method comprising inhibiting the activity of a gene product of
3 an endogenous gene having a subsequence which hybridizes under stringent
4 conditions to a sequence selected from the group consisting of SEQ. ID. 1,
5 SEQ. ID. No. 2, SEQ. ID. No. 3, SEQ. ID. No. 4, SEQ. ID. No. 5, SEQ. ID.
6 No. 6, SEQ. ID. No. 7, SEQ. ID. No. 8, SEQ. ID. NO. 9, SEQ. ID. NO. 10,
7 SEQ. ID. No. 12, and SEQ. ID. No. 13.

1 42. A method of detecting a cancer, said method comprising
2 detecting the overexpression of a protein encoded in a 20q13 amplicon.

1 43. The method of claim 41, wherein said protein encoded in
2 a 20q13 amplicon is ZABC1.

1 44. The method of claim 41, wherein said protein encoded in
2 a 20q13 amplicon is 1b1.



GENES FROM THE 20q13 AMPLICON AND THEIR USES

ABSTRACT OF THE DISCLOSURE

The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases.

K:\DATA\PS\PAT\KLB\63444.1

DECLARATION

As a below named inventor, I declare that:

99 21
My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **GENES FROM THE 20q13 AMPLICON AND THEIR USES** the specification of which is attached hereto or x was filed on 1/17/97 as Application No. 08/785,532 and was amended on (if applicable).

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign applications(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
			Yes <u> </u> No <u> </u>
			Yes <u> </u> No <u> </u>

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date



I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status		
08/731,499	10/16/96	<u> </u> Patented	<u> x </u> Pending	<u> </u> Abandoned
08/680,395	7/15/96	<u> </u> Patented	<u> x </u> Pending	<u> </u> Abandoned

Full Name of Inventor 1	Last Name Gray	First Name Joe	Middle Name or Initial W.	
Residence & Citizenship	City San Francisco	State/Foreign Country California	Country of Citizenship USA	
Post Office Address	Post Office Address 1921 11th Avenue	City San Francisco	State/Country California	Zip Code 94116
Full Name of Inventor 2	Last Name Collins	First Name Colin	Middle Name or Initial Conrad	
Residence & Citizenship	City San Rafael	State/Foreign Country California	Country of Citizenship USA	
Post Office Address	Post Office Address 333 Mountain View Avenue	City San Rafael	State/Country California	Zip Code 94901

Full Name of Inventor 3	Last Name Hwang	First Name Soo-in	Middle Name or Initial	
Residence & Citizenship	City Berkeley	State/Foreign Country California	Country of Citizenship USA	
Post Office Address	Post Office Address 189 Fairlawn Dr.	City Berkeley	State/Country California	Zip Code 94708
Full Name of Inventor 4	Last Name Godfrey	First Name Tony	Middle Name or Initial	
Residence & Citizenship	City San Francisco	State/Foreign Country California	Country of Citizenship UK	
Post Office Address	Post Office Address 699 Teresita Boulevard	City San Francisco	State/Country California	Zip Code 94127
Full Name of Inventor 5	Last Name Kowbel	First Name David	Middle Name or Initial	
Residence & Citizenship	City Oakland	State/Foreign Country California	Country of Citizenship USA	
Post Office Address	Post Office Address 6009 Auburn Avenue	City Oakland	State/Country California	Zip Code 94618
Full Name of Inventor 6	Last Name Rommens	First Name Johanna	Middle Name or Initial	
Residence & Citizenship	City Toronto	State/Foreign Country Ontario, Canada	Country of Citizenship Canada	
Post Office Address	Post Office Address 717 Bay St. #1501	City Toronto	State/Country Ontario, Canada	Zip Code M5G 2J9

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1  Joe W. Gray	Signature of Inventor 2 Colin Conrad Collins	Signature of Inventor 3 Soo-in Hwang
Date: <u>5/2/97</u>	Date:	Date:
Signature of Inventor 4  Tony Godfrey	Signature of Inventor 5 David Kowbel	Signature of Inventor 6 Johanna Rommens
Date: <u>5/2/97</u>	Date:	Date:



Attorney Docket No. 023070-068920

DECLARATION

a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **GENES FROM THE 20q13 AMPLICON AND THEIR USES** the specification of which is attached hereto or x was filed on 1/17/97 as Application No. 08/785,532 and was amended on (if applicable).

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign applications(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
			Yes <u> </u> No <u> </u>
			Yes <u> </u> No <u> </u>

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
08/731,499	10/16/96	Patented <u> x </u> Pending <u> </u> Abandoned <u> </u>
08/680,395	7/15/96	Patented <u> x </u> Pending <u> </u> Abandoned <u> </u>

Full Name of Inventor 1	Last Name Gray	First Name Joe	Middle Name or Initial W.
Residence & Citizenship	City San Francisco	State/Foreign Country California	Country of Citizenship USA
Post Office Address	Post Office Address 1921 11th Avenue	City San Francisco	State/Country California Zip Code 94116
Full Name of Inventor 2	Last Name Collins	First Name Colin	Middle Name or Initial
Residence & Citizenship	City San Rafael	State/Foreign Country California	Country of Citizenship USA
Post Office Address	Post Office Address 333 Mountain View Avenue	City San Rafael	State/Country California Zip Code 94901

(Page 1 of 2)

Full Name of Inventor 3	Last Name Hwang	First Name Soo-in	Middle Name or Initial	
Residence & Citizenship	City Berkeley	State/Foreign Country California	Country of Citizenship USA	
Post Office Address	Post Office Address 189 Fairlawn Dr.	City Berkeley	State/Country California	Zip Code 94708
Full Name of Inventor 4	Last Name Godfrey	First Name Tony	Middle Name or Initial	
Residence & Citizenship	City San Francisco	State/Foreign Country California	Country of Citizenship UK	
Post Office Address	Post Office Address 699 Teresita Boulevard	City San Francisco	State/Country California	Zip Code 94127
Full Name of Inventor 5	Last Name Kowbel	First Name David	Middle Name or Initial	
Residence & Citizenship	City Oakland	State/Foreign Country California	Country of Citizenship USA	
Post Office Address	Post Office Address 6009 Auburn Avenue	City Oakland	State/Country California	Zip Code 94618
Full Name of Inventor 6	Last Name Rommens	First Name Johanna	Middle Name or Initial	
Residence & Citizenship	City Toronto	State/Foreign Country Ontario, Canada	Country of Citizenship Canada	
Post Office Address	Post Office Address 717 Bay St. #1501	City Toronto	State/Country Ontario, Canada	Zip Code M5G 2J9

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1 Joe W. Gray	Signature of Inventor 2 Colin Collins	Signature of Inventor 3 Soo-in Hwang
Date: _____ Joe W. Gray	Date: _____ Colin Collins	Date: _____ Soo-in Hwang
Signature of Inventor 4 Tony Godfrey	Signature of Inventor 5 David Kowbel	Signature of Inventor 6 <i>Johanna Rommens</i> Johanna Rommens
Date: _____ Tony Godfrey	Date: _____ David Kowbel	Date: <i>April 2, 1997</i>



DECLARATION

As below named inventor, I declare that:

My residence, office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **GENES FROM THE 20q13 AMPLICON AND THEIR USES** the specification of which is attached hereto or x was filed on 1/17/97 as Application No. 08/785,532 and was amended on (if applicable).

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign applications(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
			Yes <u> </u> No <u> </u>
			Yes <u> </u> No <u> </u>

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date



I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status		
08/731,499	10/16/96	<u> </u> Patented	<u>x</u> Pending	<u> </u> Abandoned
08/680,395	7/15/96	<u> </u> Patented	<u>x</u> Pending	<u> </u> Abandoned

Full Name of Inventor 1	Last Name Gray	First Name Joe	Middle Name or Initial W.	
Residence & Citizenship	City San Francisco	State/Foreign Country California	Country of Citizenship USA	
Post Office Address	Post Office Address 1921 11th Avenue	City San Francisco	State/Country California	Zip Code 94116
Full Name of Inventor 2	Last Name Collins	First Name Colin	Middle Name or Initial Conrad	
Residence & Citizenship	City San Rafael	State/Foreign Country California	Country of Citizenship USA	
Post Office Address	Post Office Address 333 Mountain View Avenue	City San Rafael	State/Country California	Zip Code 94901

Full Name of Inventor 3	Last Name Hwang	First Name Soo-in	Middle Name or Initial	
Residence & Citizenship	City Berkeley	State/Foreign Country California	Country of Citizenship USA	
Post Office Address	Post Office Address 189 Fairlawn Dr.	City Berkeley	State/Country California	Zip Code 94708
Full Name of Inventor 4	Last Name Godfrey	First Name Tony	Middle Name or Initial	
Residence & Citizenship	City San Francisco	State/Foreign Country California	Country of Citizenship UK	
Post Office Address	Post Office Address 699 Teresita Boulevard	City San Francisco	State/Country California	Zip Code 94127
Full Name of Inventor 5	Last Name Kowbel	First Name David	Middle Name or Initial	
Residence & Citizenship	City Oakland	State/Foreign Country California	Country of Citizenship USA	
Post Office Address	Post Office Address 6009 Auburn Avenue	City Oakland	State/Country California	Zip Code 94618
Full Name of Inventor 6	Last Name Rommens	First Name Johanna	Middle Name or Initial	
Residence & Citizenship	City Toronto	State/Foreign Country Ontario, Canada	Country of Citizenship Canada	
Post Office Address	Post Office Address 717 Bay St. #1501	City Toronto	State/Country Ontario, Canada	Zip Code M5G 2J9

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1 Joe W. Gray	Signature of Inventor 2  Colin Conrad Collins	Signature of Inventor 3  Soo-in Hwang
Date: 5/6/97	Date: 5/6/97	Date: 5-6-97
Signature of Inventor 4 Tony Godfrey	Signature of Inventor 5  David Kowbel	Signature of Inventor 6 Johanna Rommens
Date: 5/6/97	Date: 5/6/97	Date:



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231,

May 16, 1997

TOWNSEND and TOWNSEND and CREW LLP

By *K.W. Weber*

PATENT

Attorney Docket No. 02307O-068920
UC Case No. 96-185-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
Joe W. Gray *et al.*)
Serial No.: 08/785,532)
Filed: 1/17/97)
For: GENES FROM THE 20q13 AMPLICON)
AND THEIR USES)

POWER OF ATTORNEY BY ASSIGNEE
AND EXCLUSION OF INVENTOR(S) UNDER 37 CFR § 3.71

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The undersigned assignee of the entire interest in the above-identified subject application hereby appoints Kenneth A. Weber, Reg. No. 31,677, Kevin L. Bastian, Reg. No. 34,774, M. Henry Heines, Reg. No. 28,219, William M. Smith, Reg. No. 30,223, Ellen Lauver Weber, Reg. No. 32,762, William B. Kezer, Reg. No. 37,369, Tom Hunter, Reg. No. 38,498 and Eugenia Garrett-Wackowski, Reg. No. 37,330, Jonathan A. Quine, Reg. No. P-41,261 as its attorneys to prosecute this application and to transact all business in the Patent Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with 37 CFR § 3.71.

An assignment of the entire interest in the above-identified subject application:

[] was recorded on _____ at reel/frame ____/_____.
[] is submitted herewith for recording.

Please direct all telephone calls to Jonathan A. Quine at (415) 576-0200 and all correspondence relative to said application to the following address:

Townsend and Townsend and Crew LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834

Dated: 5/14/97

ASSIGNEE: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Signature: Linda S. Stevenson

Typed Name: Linda S. Stevenson

Title: Principal Prosecution Analyst

Office of Technology Transfer
300 Lakeside Drive, 22nd Floor
Oakland, CA 94612-3550

F:\DATA\PSPTOD\MEG\72907.1




FIGURE 1

08/785532




FIGURE 2

08/785532




FIGURE 3

08/785532





FIGURE 4

08/785532

Physical map of 209 13.2

RMC20C001

Figure 5



ene ID → 1, 2

3 4, 5 6, 7, 8, 9, 10, 11 12, 13, 14, 15

108X

Genomic Sequence from BAC clone 97
Filtered query sequence:

gb|M19533|RATCYCA Rat cyclophilin mRNA, complete cds.
Length = 743

Minus Strand HSPs:

Score = 418 (115.5 bits). Expect = 1.5e-58, Sum P(5) = 1.5e-58
Identities = 96/112 (85%). Positives = 96/112 (85%). Strand = Minus /
Plus

Query: 372 TNCAATATCACCGCAGATGGCGAGCCCTTAGGCCATGTCCTCGAGCTATTGCAAGAC
313

Sbjct: 64 TTGACATCACGGCTGATGGCGAGCCCTGGCTCGCTCTGCTTCGAGCTGTTGCAGAC
123

Query: 312 AAAGTTCCAAAGACATCAGAAA~~T~~TTCATGGTCTGAGCACTGGAGAGAAAAG 261

Sbjct: 174 AAGCTTCCAAAGACACCCAGAAA~~T~~TCGTGCTCTGAGCACTGGGGAGAAAAG 175

Score = 236 (65.2 bits). Expect = 1.5e-58. Sum P(S) = 1.5e-58
Identities = 52/58 (89%). Positives = 52/58 (89%), Strand = Minus / Plus

Query: 117 TGCTGGACTCAACACAAATGGTCCCCAGTTTTCATCTGCACTGCCAAAATCGAGTGG 60
||| ||| ||| ||| ||| ||| ||| |||
Sbjct: 348 TGCTGGACCAACACAAATGGTCCCCAGTTTTATCTGCACTGCCAAGACTGAGTGG
405

Score = 177 (43.9 bits), Expect = 1.5e-52, Sum P(5) = 1.5e-58
Identities = 41/48 (85%), Positives = 41/48 (85%), Strand = Minus / Plus

Query: 60 GACTGGATGGCAAGCGTGTGATGTTGGCAAGCTGCAAGAGGGCATGA 13
| :
Sbjct: 404 GGCTGGATGGCAAGCATGTGGCTTTGGCAAGCTGAAAGAAGGCATGA 451

Score = 154 (42.6 bits), Expect = 1.5e-58, Sum P(S) = 1.5e-58
Identities = 34/38 (89%), Positives = 34/38 (89%), Strand = Minus / Plus

Query: 153 AGAACTTCGTTCTGAAACATGCAGGTCTGGCATCTTG 116
||||||| ||||| |||||
Sbjct: 299 AGAACTTCATCCCTGAAAGCATACAGGTCTGGCATCTTG 336

Score = 86 (23.8 bits), Expect = 1.5e-58, Sum P(5) = 1.5e-58
Identities = 22/28 (78%), Positives = 22/28 (78%), Strand = Minus / Plus

```

Query: 256 TCCTGCCTTGCAAGAATTATTCATTAT 229
        ||||| | | | | | | | | | | | | | |
Sbjct: 193 TCCTCCTTCAACAGAATTATTCAGGAT 220

```

Figure 6

MAIL ROOM
MAY 21 1997
PAT. & TRADEMARK OFF.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Attn: Box Missing Parts, Washington, D.C. 20231,
on

May 16, 1997
TOWNSEND and TOWNSEND and CREW LLP

By W. Gray

PATENT

Attorney Docket No. 023070-068920US
UC Case No. 96-195-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
Gray et al.) Examiner: Unassigned
Serial No.: 08/785,532) Art Unit: Unassigned
Filed: January 17, 1997) TRANSMITTAL LETTER - RESPONSE
For: GENES FROM THE 20q13) TO NOTICE OF MISSING PARTS
AMPLICON AND THEIR USES)
)

Attn: Box Missing Parts
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to the Notice to File Missing Parts of Application - Filing Date Granted dated March 24, 1997, enclosed are the following to be made of record in the above-identified application:

- 1) Executed Declaration (three fully executed Declarations);
- 2) Power of Attorney by Assignee and Exclusion of Inventor(s) Under 37 CFR §3.71;
- 3) Assignment recordation from Joe W. Gray, Colin Conrad Collins, Soo-in Hwang, Tony Godfrey and David Kowbel to The Regents of the University of California; and Assignment recordation from Johanna Rommens to The Hospital for Sick Children;
- 4) Communication under 37 C.F.R. §§1.821-1.825 and Preliminary Amendment;
- 5) The sequence listing in computer readable form;

06/20/1997 SHOPPER 00000169 DAH:201430 0878532
01 FC:103 594.00 CH 6) Diskette enclosed; and
02 FC:101 770.00 CH 7) Copy of Notice of Missing Parts
03 FC:105 130.00 CH
04 FC:102 160.00 CH

Gray et al.
Serial No.: 08/785,532
Page 2


PATENT

Please charge Deposit Account No. 20-1430 for the following fees:

(a) Filing Fee (§ 1.16(a)) (Large Entity)	\$ 770.00
(b) Excess Claims Fees (§ 1.16(b), (c)):	
<u>47</u> - 20 = <u>27</u> x 22.00 =	594.00
<u>5</u> - 3 = <u>2</u> x 80.00 =	160.00
(c) Missing Parts Surcharge (§1.16(e))	130.00
TOTAL FEES TO BE CHARGED	\$1,654.00

The Commissioner is hereby authorized to charge any additional fees associated with this paper or during the pendency of this application, or credit any overpayment to Deposit Account No. 20-1430 for this paper and during the prosecution of this application. This Transmittal Letter is submitted in triplicate.

Respectfully submitted,



Jonathan A. Quine
Reg. No. P-41,261

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
(415) 326-2400
Fax (415) 326-2422
JAQ:meg

F:\DATA\PS\PTOD\JAQ\73678.1